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Dissertation	  Abstract	  
Background	  	  
Splenectomy	  has	  been	  practiced	  for	  the	  treatment	  of	  ITP	  for	  the	  past	  few	  
decades.	  	  Currently	  it	  is	  utilised	  when	  a	  patient	  is	  either	  dependent	  or	  resistant	  
to	  steroid	  treatment	  and	  the	  platelet	  count	  remains	  less	  than	  30×109/L.	  	  
Recently	  new	  agents	  have	  been	  added	  to	  the	  armamentarium	  used	  to	  treat	  ITP,	  
including	  immunosuppressants	  such	  as	  rituximab	  and	  the	  new	  thrombopoetin-­‐
receptor	  agonists.	  	  This	  has	  brought	  into	  question	  the	  role	  of	  surgery	  for	  the	  
treatment	  of	  ITP,	  and	  the	  need	  to	  compare	  the	  response	  and	  complication	  rates	  
of	  splenectomy	  to	  these	  newer	  agents.	  	  	  
Historic	  studies	  done	  on	  splenectomy	  for	  the	  treatment	  of	  ITP	  have	  been	  
performed	  in	  the	  setting	  of	  low	  HIV	  prevalence.	  There	  is	  a	  relative	  paucity	  of	  
data	  on	  the	  response	  rate	  in	  HIV-­‐associated	  thrombocytopenia	  to	  splenectomy	  




We	  retrospectively	  analysed	  73	  consecutive	  patients	  who	  underwent	  
splenectomy	  for	  ITP	  from	  2001	  to	  2011.	  	  The	  primary	  objective	  was	  to	  
determine	  the	  rate	  of	  complete	  response,	  this	  was	  defined	  as	  a	  platelet	  count	  
greater	  than	  100×109/L	  at	  one	  year	  post	  splenectomy.	  	  Results	  were	  compared	  
between	  HIV	  positive	  and	  HIV	  negative	  patients.	  The	  secondary	  objectives	  were:	  
to	  evaluate	  the	  intra-­‐operative	  and	  post-­‐operative	  complications	  and	  mortality	  
in	  the	  HIV	  positive	  and	  HIV	  negative	  groups,	  and	  to	  investigate	  for	  associations	  
between	  co-­‐morbidities,	  pre-­‐operative	  treatment	  and	  response	  to	  splenectomy.	  	  
	  
Results	  
HIV	  status	  was	  known	  for	  58	  of	  the	  73	  patients	  included	  in	  the	  study:	  12	  were	  
HIV	  positive	  (21%),	  and	  46	  were	  HIV	  negative	  (79%).	  	  All	  patients	  had	  been	  
treated	  with	  oral	  prednisone	  at	  a	  dose	  of	  1-­‐2mg/kg/day.	  	  Median	  age	  at	  
	   iii	  
splenectomy	  was	  33	  years	  (range:	  16-­‐70	  years).	  
	  
Median	  time	  to	  splenectomy	  from	  diagnosis	  of	  ITP	  was	  14	  months	  (range	  1-­‐167	  
months).	   Splenectomies	   were	   performed	   by	   open	   laparotomy	   in	   26	   patients	  
(38%)	  and	  were	  laparoscopic	  in	  43	  (62%).	  	  The	  rate	  of	  complete	  response	  was	  
80%	   (CI	   69-­‐91%)	   -­‐	   these	   patients	  maintained	   platelet	   counts	   of	   greater	   than	  
100×109/L	  at	  one	  year	  and	  did	  not	  require	  further	  immunosuppressive	  therapy.	  	  
At	  one	  year	  there	  was	  no	  statistically	  significant	  difference	  in	  the	  platelet	  count	  
between	  HIV	  positive	  and	  negative	  patients.	  
	  
There	  were	  11	  post-­‐operative	  complications	   in	  10	  patients	  (16%	  complication	  
rate).	   	   The	   complication	   rate	   in	   the	  HIV	  positive	   patients	  was	   not	   statistically	  
significantly	  different	  to	  the	  HIV	  negative	  patients	  (18%	  and	  16%	  respectively).	  
The	   median	   post-­‐operative	   discharge	   day	   was	   day	   3	   (range:	   2-­‐8);	   with	   no	  
statistically	   significant	  difference	   in	   the	  HIV	  positive	   and	  HIV	  negative	  patient	  
groups.	  	  The	  90-­‐day	  mortality	  rate	  was	  1.38%;	  one	  of	  the	  72	  patients	  died	  at	  10	  
weeks	   post-­‐splenectomy.	   	   	   Seven	   patients	   (six	   HIV	   negative	   and	   one	   HIV	  




The	   rate	   of	   complete	   response	   was	   in	   keeping	   with	   other	   studies;	   the	  
complete	   response	   rate	   to	   splenectomy	  appears	  higher	   than	   that	   reported	   for	  
rituximab	  or	  the	  new	  thrombopoetin	  agonists.	  	  
	  
The	  results	  show	  that	  splenectomy	  is	  effective	  and	  safe	   in	   the	  HIV	  positive	  
and	   negative	   population	   and	   supports	   the	   recommendation	   that	   splenectomy	  
remains	  the	  second-­‐line	  treatment	  of	  choice,	  with	  the	  newer	  therapies	  reserved	  
for	  patients	  who	  cannot	  have	  surgery	  or	  for	  whom	  splenectomy	  fails.	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  Abbreviations	  used	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PART	  A:	  STUDY	  PROTOCOL	  
Protocol	  submitted	  for	  approval	  in	  2012:	  please	  note	  that	  there	  was	  an	  amendment	  to	  the	  
protocol	  –	  the	  dates	  for	  data	  collection	  were	  expanded	  to	  include	  2011	  data,	  this	  has	  been	  
approved	  by	  the	  UCT	  ethics	  board	  (see	  appendix	  1)	  and	  the	  UCT	  Internal	  Medicine	  M.	  Med	  
committee.	  	  
	  
The	  protocol	  contains	  a	  brief	  review	  of	  the	  literature	  as	  an	  introduction	  and	  background	  for	  
the	  study	  protocol;	  to	  avoid	  repetition	  it	  is	  suggested	  that	  the	  examiner	  preferentially	  reads	  
Part	  B	  (Literature	  review).	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I. PROTOCOL   
 
1. Introduction  
 
Immune	  thrombocytopenia	  (ITP)	  is	  a	  condition	  of	  excessive	  platelet	  destruction	  
(due	  to	  autoantibodies)	  with	  an	  inadequate	  or	  absent	  compensatory	  bone	  
marrow	  response,	  which	  results	  in	  a	  low	  platelet	  count.	  	  ITP	  can	  be	  acute	  (most	  
common	  in	  childhood,	  and	  usually	  post-­‐viral	  infection)	  or	  chronic.	  	  Chronic	  ITP	  
can	  be	  idiopathic	  or	  secondary	  to:	  autoimmune	  disorders	  (such	  as	  SLE,	  Evans	  
syndrome,	  thyroid	  disease);	  infections	  	  (HIV	  infection,	  hepatitis	  and	  h.	  pylori);	  
drugs;	  and	  lymphoproliferative	  disease.	  Most	  important	  in	  our	  context	  is	  the	  
association	  with	  HIV	  infection.	  	  
	  
In	  HIV	  infection	  thrombocytopenia	  is	  the	  second	  most	  common	  haematological	  
abnormality	  (after	  anaemia)	  and	  the	  causes	  are	  multifactorial	  including:	  
autoimmune	  destruction	  of	  platelets	  and	  marrow	  suppression	  and	  
megakaryocyte	  dysfunction	  (from	  direct	  HIV	  infection,	  cytokine	  storm,	  drugs	  
and	  co-­‐morbid	  conditions	  such	  as	  TB	  and	  CMV).	  The	  current	  best	  medical	  
practice	  to	  manage	  ITP	  in	  HIV	  is	  with	  antiretroviral	  therapy	  and	  glucocorticoids.	  
But	  there	  is	  a	  paucity	  of	  data	  on	  the	  quality	  of	  the	  response	  to	  steroids,	  the	  
relapse	  rate	  and	  in	  particular,	  the	  longer-­‐term	  outcome	  of	  these	  patients	  (1).	  
There	  have	  been	  a	  few	  studies	  that	  have	  demonstrated	  that	  splenectomy	  as	  a	  
treatment	  for	  HIV-­‐ITP	  is	  safe	  and	  effective	  (to	  be	  discussed	  in	  more	  detail	  
below)	  and	  after	  initial	  concerns	  in	  the	  pre-­‐cART	  era	  that	  splenectomy	  caused	  a	  
more	  rapid	  progression	  to	  AIDS	  were	  dispelled	  (9),	  it	  has	  been	  a	  more	  
commonly	  used	  strategy.	  There	  is	  however	  no	  data	  of	  outcomes	  from	  the	  South	  
African	  context	  on	  the	  effectiveness	  of	  splenectomy	  in	  the	  HIV	  positive	  
population;	  this	  would	  be	  important	  and	  relevant	  to	  obtain	  because	  of	  the	  high	  
rate	  of	  other	  co-­‐morbidities	  in	  HIV	  thrombocytopenia	  (i.e.	  TB)	  and	  because	  
there	  are	  other	  medical	  treatments	  that	  could	  potentially	  be	  employed	  prior	  to	  a	  
surgical	  procedure.	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The	  prevalence	  of	  thrombocytopenia	  in	  HIV	  shows	  a	  bimodal	  distribution	  with	  
a	  peak	  in	  early	  HIV	  and	  then	  again	  in	  advanced	  HIV,	  but	  may	  occur	  at	  any	  time	  
during	  the	  course	  of	  the	  infection.	  The	  reported	  prevalence	  varies	  depending	  on	  
the	  source,	  but	  stated	  to	  occur	  in	  as	  many	  as	  40%	  of	  HIV	  infected	  individuals	  
(2);	  according	  to	  another	  source	  chronic	  thrombocytopenia	  occurs	  in	  about	  
10%	  of	  HIV-­‐infected	  patients,	  and	  up	  to	  a	  third	  of	  patients	  with	  AIDS(3).	  The	  
prevalence	  of	  platelet	  count	  less	  than	  50×109/L	  is	  seen	  in	  1-­‐5%	  of	  cases	  (3),	  
with	  one	  large	  study	  reporting	  the	  incidence	  at	  3.2%	  in	  the	  cART	  era	  (4).	  	  
	  
There	  are	  no	  South	  African	  data	  on	  prevalence	  of	  HIV-­‐ITP,	  but	  it	  is	  likely	  to	  be	  
affected	  by	  the	  local	  occurrence	  of	  conditions	  associated	  with	  HIV-­‐ITP	  such	  as:	  
co-­‐infection	  with	  Hepatitis	  B	  and	  C	  (4,5);	  prevalence	  of	  drug	  use	  
(thrombocytopenia	  has	  been	  shown	  to	  be	  more	  severe	  in	  HIV-­‐infected	  drug	  
users)	  (6);	  and	  nutritional	  status	  as	  HIV-­‐ITP	  has	  also	  been	  associated	  with	  poor	  
nutritional	  status	  (specifically	  selenium	  deficiency)(6).	  	  
	  
Thrombocytopenia	  is	  an	  important	  problem	  in	  HIV,	  both	  because	  it	  is	  common	  
and	  because	  it	  is	  associated	  with	  significant	  morbidity	  and	  mortality.	  
Thrombocytopenia	  has	  been	  associated	  with	  rapid	  progression	  to	  AIDS,	  this	  is	  
thought	  in	  part	  to	  be	  due	  to	  the	  association	  of	  thrombocytopenia	  with	  a	  high	  
viral	  load	  (2,	  6,	  7).	  It	  is	  also	  associated	  with	  an	  increased	  risk	  of	  bleeding	  and	  
haemorrhagic	  complications.	  	  
	  
The	  mechanisms	  by	  which	  HIV	  infection	  can	  cause	  thrombocytopenia	  are	  
multiple	  and	  vary	  depending	  on	  the	  stage	  of	  HIV	  infection.	  These	  mechanisms	  
include:	  direct	  infection	  of	  the	  platelets	  and	  megakaryocytes	  with	  HIV	  through	  
the	  CD4	  and	  CXCR4	  receptors	  (6),	  increased	  peripheral	  platelet	  destruction,	  and	  
myelosuppresion	  secondary	  to	  increased	  susceptibility	  to	  opportunistic	  
infections	  such	  as	  CMV	  and	  TB	  and	  antiretroviral	  agents.	  	  
	  
Early	  in	  HIV	  the	  predominant	  mechanism	  is	  increased	  peripheral	  consumption.	  
Multiple	  auto-­‐antibodies	  and	  cross-­‐reactive	  antibodies	  have	  been	  identified	  
which	  ultimately	  result	  in	  increased	  platelet	  destruction	  via	  Fcγ-­‐mediated	  
phagocytosis	  by	  macrophages	  in	  the	  spleen	  or	  complement-­‐	  independent	  
platelet	  fragmentation	  by	  the	  generation	  of	  peroxide	  (5).	  These	  antibodies	  are	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multiple,	  but	  include:	  anti-­‐glycoprotein	  (GP)IIb	  and/or	  GPIIIa	  (however,	  cross-­‐
reactive	  antibody	  between	  HIV	  gp160/120	  and	  platelet	  GPIIb/IIIa	  has	  also	  been	  
demonstrated)(1)	  and	  more	  recently	  an	  anti-­‐	  talin	  antibody	  that	  attacks	  the	  
cytoskeleton	  of	  the	  platelet	  has	  been	  identified	  (7).	  Talin	  cross-­‐links	  actin	  
filaments	  and	  cytoplasmic	  tails	  of	  beta	  integrins	  at	  focal	  adhesion	  points	  within	  
platelets.	  	  
	  
Late	  in	  HIV,	  the	  predominant	  cause	  of	  thrombocytopenia	  is	  inadequate	  
thrombopoesis	  –	  secondary	  to	  ‘cytokine	  storm’	  in	  the	  bone	  marrow	  
(unmitigated	  cytokine	  release)	  and	  direct	  infection	  of	  the	  megakaryocytes	  (1).	  
Megakaryocytes	  bear	  CD4+	  receptors	  capable	  of	  binding	  HIV-­‐1	  as	  well	  as	  the	  co-­‐
receptor	  molecule	  CXCR4	  (13)	  which	  enable	  HIV-­‐1	  viral	  entry	  into	  the	  
megakaryocyte	  and	  interfere	  with	  normal	  platelet	  production.	  Late	  in	  HIV	  there	  
is	  also	  increased	  susceptibility	  to	  intercurrent	  opportunistic	  infections	  that	  may	  
cause	  bone	  marrow	  suppression	  (in	  our	  setting,	  TB	  being	  the	  most	  important	  
condition	  to	  exclude).	  But	  this	  is	  likely	  an	  over-­‐simplification	  in	  terms	  of	  the	  
pathogenesis	  at	  early	  and	  late	  HIV;	  with	  an	  imbalance	  of	  marrow	  production,	  
shorted	  platelet	  lifespan	  and	  immune	  destruction	  present	  in	  variable	  degrees	  
throughout	  the	  course	  of	  HIV.	  	  
	  
Patients	  with	  HIV-­‐ITP	  have	  increased	  megakaryocyte	  mass	  as	  seen	  on	  bone	  
marrow	  biopsy,	  as	  well	  as	  a	  six-­‐fold	  increase	  in	  thrombopoetin	  levels	  (13)	  but	  
this	  is	  inadequate	  to	  compensate	  for	  the	  amplified	  peripheral	  consumption	  as	  




Treatment	  guidelines	  for	  HIV-­‐associated	  thrombocytopenia	  have	  not	  yet	  been	  
formalised	  because	  of	  a	  lack	  of	  high-­‐quality	  clinical	  trials.	  Treatment	  is	  therefore	  
mainly	  based	  on	  expert	  opinion,	  and	  has	  followed	  the	  treatment	  of	  ITP	  in	  HIV-­‐ve	  
patients	  (2).	  	  
Destruction	  and	  production	  of	  platelets	  are	  mediated	  at	  many	  different	  levels	  
and	  therefore	  the	  various	  treatment	  strategies	  aim	  to	  target	  these	  levels.	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Medical Treatment  
Glucocorticoids	  work	  by	  inhibiting	  the	  expression	  of	  splenic	  macrophage	  Fc	  
receptors,	  and	  thereby	  decreasing	  the	  splenic	  destruction	  of	  platelets.	  Steroids	  
also	  inhibit	  the	  lymphoid	  clone	  that	  produces	  the	  auto	  antibody	  leading	  to	  
improvement	  of	  platelet	  counts	  in	  patients	  who	  display	  adequate	  marrow	  
compensation.	  However	  glucocorticoids	  at	  high	  doses	  have	  high	  risks	  in	  HIV	  
positive	  patients:	  steroids	  can	  directly	  up-­‐regulate	  HIV-­‐1	  replication,	  as	  well	  as	  
increase	  the	  risk	  of	  opportunistic	  infections	  (2).	  Prednisone	  can	  produce	  an	  
increase	  of	  the	  platelet	  count	  to	  over	  100×109/L	  in	  over	  half	  of	  patients	  treated,	  
but	  only	  a	  minority	  of	  patients	  will	  maintain	  platelets	  above	  50	  after	  cessation	  
of	  therapy(2).	  	  
	  
Danazol	  (an	  attenuated	  androgen)	  has	  been	  used	  with	  mixed	  results	  –	  its	  overall	  
efficacy	  has	  been	  shown	  to	  be	  quite	  unsatisfactory	  in	  HIV	  positive	  patients	  (2).	  	  
	  
Very	  small	  studies	  have	  tested	  dapsone	  to	  treat	  HIV-­‐associated	  
thrombocytopenia,	  and	  they	  have	  shown	  some	  success.	  It	  is	  hypothesized	  that	  it	  
acts	  by	  a	  competitive	  effect	  on	  red	  cell	  clearance	  by	  the	  reticuloendothelial	  
system	  (14).	  	  
	  
Intravenous	  immune	  globulin	  produces	  significant	  improvement	  in	  the	  majority	  
of	  patients	  with	  HIV	  associated	  thrombocytopenia	  (over	  90%	  reported	  in	  a	  
review	  of	  cases),	  and	  the	  response	  rate	  is	  typically	  very	  rapid,	  usually	  after	  one	  
dose.	  But	  its	  use	  is	  limited	  because	  the	  response	  is	  typically	  transient,	  and	  so	  
multiple	  infusions	  may	  be	  required,	  at	  a	  high	  cost	  (14).	  It	  is	  thought	  to	  work	  by	  
saturating	  the	  Fc	  receptors	  in	  the	  spleen,	  thereby	  preventing	  the	  removal	  of	  
platelets.	  	  
	  
Anti-­‐Rhesus	  immunoglobulin	  is	  a	  solution	  of	  IgG	  anti-­‐D	  (anti-­‐RhD)	  antibodies,	  it	  
has	  shown	  to	  have	  a	  similar	  response	  rate	  to	  IVIG,	  at	  less	  cost,	  but	  the	  concern	  is	  
that	  it	  can	  lead	  to	  haemolysis	  and	  for	  this	  reason	  it	  can	  only	  be	  given	  to	  patients	  
with	  an	  adequate	  haemoglobin,	  and	  who	  are	  Rhesus	  positive	  (2).	  It	  works	  by	  the	  
competitive	  binding	  of	  Fc	  receptors	  in	  the	  spleen	  (Rh-­‐	  antigen	  binds	  to	  the	  red	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cell	  membrane,	  the	  sensitised	  RBCs	  are	  cleared	  by	  the	  spleen)	  and	  
consequent	  reduction	  in	  platelet	  clearance.	  	  
	  
Anti-­‐retroviral	  agents	  were	  initially	  thought	  to	  raise	  platelet	  count	  by	  
decreasing	  the	  HIV	  viral	  load	  burden;	  this	  is	  now	  thought	  to	  likely	  not	  be	  the	  full	  
mechanism,	  since	  certain	  antiretroviral	  agents	  are	  better	  than	  others	  at	  raising	  
platelet	  count.	  In	  the	  years	  before	  cART;	  numerous	  studies	  demonstrated	  that	  
zidovudine	  (AZT)	  mono	  therapy	  was	  shown	  to	  be	  efficacious	  in	  increasing	  the	  
platelet	  count	  (10).	  In	  one	  study	  comparing	  cART	  to	  AZT	  mono	  therapy;	  
response	  rates	  to	  cART	  have	  been	  found	  to	  be	  similar.	  cART	  was	  found	  to	  
increase	  the	  platelet	  count	  to	  above	  50	  x	  10^9/L	  in	  73%	  of	  patients,	  with	  a	  
complete	  response	  (increase	  of	  platelets	  >	  100	  x	  10^9/L)	  in	  53%	  of	  patients;	  
this	  response	  occurred	  within	  the	  third	  month	  of	  treatment	  and	  was	  sustained	  
throughout	  the	  treatment	  period(10).	  A	  limitation	  of	  AZT	  is	  that	  it	  can	  directly	  
cause	  marrow	  suppression	  leading	  to	  leukopenia	  and	  anaemia.	  Antiretroviral	  
drugs	  will	  decrease	  the	  viral	  load	  and	  number	  of	  infected	  cells	  in	  the	  bone	  
marrow,	  and	  decrease	  the	  ‘cytokine	  storm’	  in	  the	  bone	  marrow	  but	  they	  may	  
not	  modify	  the	  formation	  of	  anti-­‐platelet	  antibodies.	  	  
	  
Recently	  rituximab	  has	  been	  added	  to	  the	  armamentarium	  to	  treat	  ITP,	  but	  it	  
has	  not	  been	  studied	  systematically	  in	  HIV	  associated	  thrombocytopenia.	  
Currently	  it	  has	  been	  used	  in	  heavily	  treated	  patients,	  in	  the	  setting	  where	  
splenectomy	  has	  either	  failed	  or	  the	  patient	  has	  contraindications	  to	  
splenectomy.	  Rituximab	  is	  a	  monoclonal	  antibody	  against	  CD20+	  B	  cells	  –	  its	  
mechanism	  of	  action	  is	  thought	  to	  be	  due	  to	  B	  cell	  depletion	  (however	  B	  cell	  
depletion	  occurs	  in	  all	  patients	  whereas	  a	  clinical	  response	  does	  not,	  and	  the	  
time	  to	  clinical	  response	  with	  an	  increase	  in	  platelet	  count	  is	  often	  irrespective	  
of	  immunoglobulin	  levels),	  and	  so	  other	  mechanisms	  have	  been	  proposed	  
including	  Fc	  receptor	  saturation	  in	  the	  spleen	  with	  resultant	  incompetence	  to	  
bind	  platelets(11)	  and	  increased	  activity	  of	  T	  cell	  regulatory	  cells	  (12).	  In	  a	  
recent	  meta-­‐analysis	  the	  rate	  of	  long-­‐term	  complete	  response	  was	  20%,	  with	  an	  
overall	  response	  rate	  of	  57%	  (increase	  in	  platelet	  count	  to	  >100,	  but	  the	  mean	  
duration	  of	  response	  was	  43	  weeks)(11).	  Rituximab	  is	  generally	  safe	  –	  however	  
it	  depletes	  antibody	  producing	  lymphocytes	  and	  further	  immunosuppression	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needs	  to	  be	  considered	  in	  the	  HIV	  positive	  population.	  Its	  use	  is	  limited	  by	  
high	  cost.	  	  
 
Surgical Treatment  
Splenectomy	  is	  generally	  reserved	  for	  those	  patients	  who	  have	  failed	  medical	  
therapy.	  In	  our	  setting,	  it	  is	  used	  after	  patients	  have	  failed	  steroid	  therapy.	  	  
Splenectomy	  has	  been	  shown	  to	  be	  both	  relatively	  safe	  in	  HIV,	  as	  well	  as	  
efficacious	  (5).	  In	  a	  systematic	  review	  published	  in	  2004	  by	  Kojouri	  	  et	  al	  
complete	  response	  (defined	  as	  achievement	  and	  maintenance	  of	  a	  normal	  
platelet	  count	  (150×109/L)	  for	  all	  measurements	  30	  days	  or	  longer	  after	  
splenectomy,	  and	  with	  no	  additional	  treatment	  for	  ITP)	  following	  splenectomy	  
was	  reported	  to	  reach	  60%	  (8).	  In	  a	  different	  article,	  Oksenhendler	  et	  al	  
reported	  long-­‐term	  experience	  in	  a	  cohort	  of	  185	  patients	  with	  HIV-­‐ITP	  (9).	  
Splenectomy	  was	  performed	  in	  68	  of	  these	  patients,	  at	  an	  average	  of	  13	  months	  
from	  initial	  diagnosis	  of	  HIV-­‐ITP.	  A	  response	  was	  seen	  in	  92%	  of	  patients	  and	  
maintenance	  of	  the	  elevated	  platelet	  count	  for	  longer	  than	  6	  months	  was	  
documented	  in	  82%.	  However	  in	  some	  studies,	  as	  many	  as	  a	  third	  of	  the	  HIV	  
positive	  patients	  who	  underwent	  splenectomy	  displayed	  an	  incomplete	  
response	  to	  the	  treatment	  (2).	  A	  problem	  when	  reviewing	  these	  articles	  is	  that	  
‘complete	  response’	  is	  defined	  differently,	  and	  the	  studies	  often	  use	  platelet	  
count	  at	  one	  month	  to	  determine	  response	  but	  we	  know	  that	  patients	  can	  later	  
relapse,	  we	  therefore	  are	  still	  unsure	  about	  the	  durability	  of	  splenectomy.	  	  
	  
In	  the	  review	  by	  Kojouri,	  the	  mortality	  rate	  of	  splenectomy	  was	  reported	  0.2%	  
and	  1.0%	  for	  laparoscopy	  and	  open	  laparotomy,	  respectively	  (8).	  Mortality	  was	  
primarily	  due	  to	  bleeding,	  sepsis	  (pneumonias	  and	  sub	  diaphragmatic	  
abscesses)	  and	  venous	  thromboembolism.	  Late	  complications	  were	  not	  
reviewed.	  In	  the	  Oksenhendler	  series	  5.8%	  of	  patients	  undergoing	  splenectomy	  
experienced	  fulminant	  infection,	  consisting	  of	  Streptococcus	  pneumoniae	  
meningitis	  in	  two	  and	  Haemophilus	  influenzae	  sepsis	  in	  one	  individual(9).	  	  
Splenectomy	  is	  therefore	  not	  a	  definitive	  or	  curative	  treatment	  for	  many	  
patients	  and	  it	  carries	  a	  risk	  of	  increased	  susceptibility	  to	  infections	  as	  well	  as	  
operative	  risks	  and	  is	  therefore	  only	  used	  after	  medical	  treatment	  has	  failed.	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2. Justification  
We	  want	  to	  compare	  the	  outcome	  in	  HIV	  positive	  and	  HIV	  negative	  patients	  (in	  
terms	  of	  response	  to	  splenectomy	  and	  survival),	  and	  report	  on	  the	  complication	  
rate	  and	  rate	  of	  opportunistic	  infections	  in	  these	  two	  groups.	  The	  justification	  
for	  carrying	  out	  this	  research	  is	  that	  we	  will	  be	  able	  to	  define	  better	  the	  
population	  of	  patients	  requiring	  splenectomy	  for	  the	  management	  of	  ITP.	  We	  
may	  be	  able	  to	  ascertain	  indicators	  that	  can	  predict	  failure	  to	  steroid	  treatment.	  
Finally,	  as	  splenectomy	  is	  an	  irreversible	  procedure	  and	  there	  is	  alternative	  
medical	  treatment	  available	  for	  HIV-­‐ITP,	  we	  need	  to	  question	  whether	  it	  is	  still	  
appropriate	  to	  offer	  splenectomy	  after	  the	  failure	  of	  steroids	  in	  the	  HIV	  positive	  
population.	  	  
 
3. Hypothesis  
We	  postulate	  that	  in	  HIV	  positive	  patients	  the	  response	  rate	  to	  splenectomy	  is	  
lower	  since	  the	  pathogenesis	  involves	  decreased	  production	  as	  well	  as	  
increased	  consumption	  of	  platelets.	  In	  addition	  we	  advance	  that	  in	  this	  patient	  
group	  there	  is	  a	  higher	  rate	  of	  post-­‐operative	  as	  well	  as	  long	  term	  
complications.	  However,	  including	  only	  patients	  that	  underwent	  splenectomy	  
selects	  out	  the	  most	  symptomatic	  cases	  of	  ITP	  and	  in	  the	  literature	  the	  response	  
rates	  for	  both	  groups	  is	  around	  60%.	  	  
 
II. METHODS  
 
1. Study Design  
The	  study	  design	  will	  be	  a	  retrospective	  cross-­‐sectional	  descriptive	  and	  
analytical	  study	  of	  patients	  who	  underwent	  splenectomy	  for	  ITP.	  The	  sequential	  
names	  of	  patients	  who	  underwent	  splenectomy	  cases	  will	  be	  retrieved	  from	  the	  
NHLS	  laboratory	  information	  system	  and	  their	  outcomes	  will	  be	  studied	  from	  
the	  clinical	  charts.	  	  
 
2. Subject Identification  
The	  patients	  chosen	  will	  be	  the	  patients	  who	  have	  undergone	  splenectomy	  for	  
ITP	  in	  the	  period	  2000-­‐2010.	  This	  population	  is	  the	  group	  of	  patients	  with	  ITP	  
as	  defined	  by	  low	  platelet	  count	  and	  bone	  marrow	  findings	  showing	  increased	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megakaryocyte	  mass	  who	  have	  relapsed	  after	  steroid	  and	  or	  other	  medical	  
therapy.	  	  
 
3. Measurement  
i. A	  data	  capture	  sheet	  will	  be	  used	  for	  record	  review	  (taken	  from	  the	  
folders	  of	  selected	  individuals).	  The	  data	  capture	  sheet	  will	  include:	  	  
• Clinical	  information	  	  
i. Patient	  demographic	  details	  	  
ii. Current	  co	  morbidities	  (TB,	  malignancy,	  etc)	  	  
iii. Concomitant	  medication	  ,	  type	  of	  cART	  
• Laboratory	  data	  	  
i. Bone	  marrow	  finding	  compatible	  with	  ITP	  –	  yes	  or	  no	  	  
ii. HIV	  status	  	  
iii. Viral	  load,	  CD4	  counts	  	  
• Other	  co-­‐morbidities	  	  
i. Platelet	  count	  at	  diagnosis	  /	  three	  month	  /	  six	  month	  /	  1	  yr	  
and	  pre-­‐splenectomy	  
ii. Platelet	  count	  6	  months	  post	  splenectomy	  and	  1	  year	  post	  
splenectomy	  	  
• Treatment	  given:	  	  
i. Steroids	  –	  duration	  and	  dosage	  per	  kg	  if	  available	  	  
1.	  Quality	  of	  response	  	  
2.	  Recurrence	  rate	  	  
ii. Other	  treatment	  given	  prior	  to	  splenectomy	  	  
iii. Length	  of	  time	  on	  ARVs	  	  
• Post	  splenectomy	  immunosuppressive	  therapies	  	  
• Rate	  of	  infections,	  particularly	  OPSI	  	  
• Peri-­‐operative	  morbidity	  and	  mortality	  	  
• Pre-­‐operative	  management	  	  
i. Plasmapheresis	  	  
ii. Serum	  immunoglobulins	  	  
iii. Platelet	  transfusions	  	  
ii. Variables:	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•	  Gender	  
•	  HIV	  status	  (binary	  variable)	  	  
iii.	  Quality	  Control:	  	  
• The	  patients	  will	  be	  identified	  using	  NHLS	  records	  of	  spleen	  histology	  
results	  for	  ITP,	  and	  double	  checked	  with	  the	  surgical	  notebooks.	  	  
• The	  data	  taken	  from	  the	  folders	  will	  include	  treatment,	  patient	  
demographic	  details,	  co-­‐morbidities	  and	  outcome.	  	  
	  
III. ANALYSIS and STATISTICS  
The	  data	  will	  be	  collated	  onto	  a	  single	  page	  summary	  table.	  These	  data	  will	  be	  
entered	  into	  MS	  Excel.	  The	  rate	  of	  treatment	  outcome	  after	  splenectomy	  will	  be	  
correlated	  with	  HIV	  status,	  as	  well	  as	  the	  rate	  of	  short	  and	  long	  term	  
complications,	  including	  OPSIs.	  An	  odds	  ratio	  will	  be	  calculated	  to	  determine	  the	  
likelihood	  of	  treatment	  success	  in	  the	  two	  groups.	  The	  length	  of	  treatment	  time	  
prior	  to	  splenectomy	  will	  be	  compared	  in	  the	  HIV	  negative	  versus	  HIV	  positive	  
groups.	  	  
 
IV. ETHICS  
The	  study	  will	  be	  submitted	  to	  the	  Ethics	  committee	  of	  the	  UCT	  for	  approval.	  
The	  names	  of	  the	  patients	  used	  in	  the	  study	  will	  be	  kept	  confidential.	  Since	  the	  
study	  involves	  a	  folder	  review	  and	  no	  intervention	  I	  do	  not	  think	  that	  the	  
patients	  included	  into	  the	  study	  need	  to	  be	  contacted	  for	  informed	  consent.	  I	  
have	  privileged	  access	  to	  both	  the	  NSHL	  and	  GSH	  records	  by	  virtue	  of	  being	  
employed	  as	  a	  medical	  doctor	  at	  GSH.	  	  
 
V. LOGISTICS  
1. Timing  
Data	  collection	  and	  entry	  onto	  excel:	  October	  2012	  
Synthesis	  and	  analysis	  of	  data:	  April	  2013	  (during	  M.	  Med	  rotation).	  Writing	  up	  
M.	  Med:	  April	  2013	  	  
 
2. Budget  
The	  study	  will	  not	  require	  external	  funding.	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  PART B : Literature Review 
	  
The	   objectives	   of	   this	   literature	   review	   were	   to	   appraise	   published	   evidence	  
addressing:	  
1) The	   mechanism	   of	   disease	   in	   immune	   thrombocytopenia	   (ITP)	   and	   in	  
Human	  Immunodeficiency	  Virus	  (HIV)-­‐associated	  thrombocytopenia	  
2) The	  response	  rates	  and	  side-­‐effects	  of	  current	  medical	  therapy	  for	  ITP	  	  
3) The	   published	   data	   on	   splenectomy:	   response	   rates,	   rates	   of	   relapse,	  
long-­‐term	  outcomes,	  and	  complications	  
	  
The	  following	  databases	  were	  searched	  for	  relevant	  literature	  via	  the	  University	  
of	   Cape	   Town	   EZproxy	   system:	   PubMed,	   Google	   Scholar,	   EBSCOHost,	   and	   the	  
Cochrane	   database	   using	   the	   keywords:	   HIV	   and	   ITP;	   HIV	   and	  
thrombocytopenia;	   Splenectomy	   for	   ITP;	   rituximab	   for	   ITP;	   thrombopoeitin	  
agonists	  for	  ITP;	  South	  Africa	  ITP;	  HAART	  (highly	  active	  antiretroviral	  therapy)	  
for	   ITP.	   Articles	   published	   from	   1985-­‐2013	  were	   included.	   	   Sixty-­‐six	   relevant	  
studies	  were	  identified.	  	  These	  studies	  included:	  eight	  on	  mechanism	  of	  disease	  
in	  ITP,	  two	  on	  natural	  history	  and	  mortality	  in	  ITP,	  eight	  on	  thrombocytopenia	  
in	   HIV,	   seven	   on	   splenectomy	   for	   ITP	   (including	   one	   review	   article),	   four	   on	  
response	   to	   steroids,	   two	   studies	   on	   rituximab	   in	   ITP	   and	   four	   studies	   on	  
thrombopoetin	  agonists	  (eltrombopag	  and	  romiplostim).	  
 
 
1.)	  Mechanism	  of	  disease	  in	  ITP	  and	  HIV	  associated	  thrombocytopenia	  
	  
Platelets	   are	   cell	   fragments	   (without	   a	   nucleus)	   that	   play	   an	   essential	   role	   in	  
haemostasis	  by	  forming	  an	  haemostatic	  plug	  and	  activating	  the	  clotting	  cascade	  
to	   form	   a	   thrombus.	   Platelets	   are	   formed	   predominately	   in	   the	   bone	  marrow	  
from	   megakaryocytes	   (about	   7-­‐15%	   of	   thrombopoesis	   is	   extramedullary).	  	  
Approximately	   2×1011	   platelets	   are	   produced	   every	   day.	   	   Under	   conditions	   of	  
increased	  platelet	  consumption	  this	  can	  increase	  eight	  times	  and	  is	  regulated	  by	  
thrombopoetin.	   	  Platelets	  have	  a	   life	  span	  of	  7-­‐10	  days	  and	  are	  cleared	  by	   the	  
cells	  of	  the	  reticuloenthothelial	  system	  including	  the	  spleen(1).	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Immune	   thrombocytopenia	   (ITP)	   is	   an	  autoimmune	  disorder	   characterized	  by	  
immunologic	   destruction	   of	   platelets,	   as	   well	   as	   an	   inadequate	   bone	  marrow	  
response	   to	   low	   platelets.	   ITP	   can	   be	   primary	   or	   secondary	   to:	   autoimmune	  
disorders	  (such	  as	  SLE,	  Evans	  syndrome,	  thyroid	  disease),	  infections	  (HIV,	  viral	  
hepatitis	   and	   H.	   pylori),	   drugs	   and	   lymphoproliferative	   disease.	   	   The	   overall	  
incidence	   of	   ITP	   (using	   a	   platelet	   count	   of	   <	   150×109/L)	   in	   adults	   has	   been	  
estimated	   at	   3.9	   per	   100,000	   person-­‐years(2)	   with	   a	   prevalence	   of	  
50.29/100,000(3).	  	  These	  data	  are	  from	  recent	  large	  studies	  in	  Europe;	  there	  are	  
no	  data	  available	  on	  prevalence	  in	  South	  Africa.	  
	  
Pathophysiology	  
Thrombocytopenia	  in	  ITP	  is	  complex	  and	  predominately	  due	  to	  platelet-­‐reactive	  
autoantibody	   production,	   along	   with	   T-­‐cell	   abnormalities	   and	   immune-­‐
mediated	  megakaryoctye	  injury	  and	  dysfunction	  that	  results	  in	  relative	  platelet	  
underproduction(4-­‐8).	  	  	  	  
	  
Historic	  studies	  by	  Harrington	  and	  Holingsworth	  in	  the	  1950’s(9)	  demonstrated	  
that	   the	   transfer	   of	   plasma	   from	   ITP	   patients	   induced	   thrombocytopenia	   in	  
healthy	   recipients.	   Subsequent	   studies	   by	   Shulman	  et	   al	   identified	   the	  plasma	  
substance	  as	  IgG	  antibodies	  against	  platelet	  glycoproteins(10,11).	  Auto-­‐antibodies	  
in	   ITP	   are	   primarily	   directed	   against	   the	   glycoproteins	   GPIIb/IIIa	   or	   GPIb/IX.	  
The	   formation	   of	   these	   auto-­‐antibodies	   is	   most	   often	   idiopathic	   but	   is	  
sometimes	   due	   to	   cross-­‐reactive	   antibody	   production	   after	   an	   infection	   (e.g.	  
HIV,	  hepatitis	  C	  and	  H.	  pylori)(4).	  	  
	  
Opsonised	  platelets	  are	   removed	   from	   the	  circulation	  by	   splenic	  macrophages	  
via	   low-­‐affinity	   Fc	   receptors.	   	   The	   peptide	   fragments	   expressed	   within	   MHC	  
class	   II	   on	   the	   macrophages	   stimulate	   helper	   T	   cells,	   which	   results	   in	   the	  
activation	  of	  B	  cells	  to	  continue	  to	  produce	  autoantibodies(4).	  	  The	  T	  helper	  cell	  
response	   is	   abnormal	   in	   ITP,	   with	   studies	   showing	   an	   imbalance	   in	   Th1/Th2	  
ratios(6).	   	  A	  decrease	   in	   the	  number	  of	   regulatory	  T	  cells	   (Treg)	  may	  partly	  be	  
responsible	   for	   this	   heightened	   Th1	   response	   –	   it	  was	   recently	   demonstrated	  
that	   in	  mice	  that	  were	  Treg-­‐deficient,	  50%	  became	  thrombocytopenic(8).	  Auto-­‐
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reactive	  T	   cell	   clones	   against	  GPIIb/IIIa	   epitopes	   in	   ITP	  patients	   have	   been	  
identified,	  which	  adds	  further	  complexity	  to	  the	  pathogenesis	  of	  ITP	  as	  well	  as	  a	  
possible	  new	  treatment	  target(7).	  	  
	  
Despite	   the	   increase	   in	   platelet	   destruction	   in	   ITP,	   there	   is	   a	   sub-­‐maximal	  
response	   to	   increase	   platelet	   production.	   	   Morphological	   abnormalities	   of	  
megakaryoctytes	   in	   ITP	  were	   first	  demonstrated	   in	   the	  1940’s,(12)	  and	  platelet	  
kinetic	   studies	   have	   shown	   platelet	   production	   remains	   unchanged	   or	   is	  
decreased	   in	   patients	   with	   ITP(13).	   	   Megakaryocytes	   at	   the	   maturation	   phase	  
contain	   glycoproteins	   GPIIb/IIIa	   or	   GPIb/IX(14)	   and	   it	   is	   thought	   that	   the	  
autoantibodies	  probably	  also	  affect	  platelet	  production	  by	  immune	  destruction	  
of	  megakaryoctes.	   	   Further	   supporting	   evidence	   for	   this	   hypothesis	   is	   that	   in	  
vitro	  studies	  have	  shown	  suppression	  of	  megakaryocyte	  growth	  and	  maturation	  
by	   the	   IgG	   fraction	  of	   ITP	  plasma(15).	   	   See	  Figure	  one	   for	  an	   illustration	  of	   the	  
combination	   of	   immune	   system	   abnomalities	   which	   contributes	   to	   increased	  
platelet	  destruction	  and	  decreased	  platelet	  production.	  	  
	  
	  
Fig	  1.	  Demonstrating	  the	  pathophysiology	  of	  ITP:	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1. Autoreactive	   antibodies	   bind	   to	   platelets	   and	   facilitate	   macrophage	  
destruction	  in	  the	  spleen;	  peptide	  fragments	  expressed	  on	  the	  surface	  of	  
the	  macrophages	  stimulate	  the	  Th	  cells	  which	  further	  activates	  B	  cells	  to	  
produce	  more	  antibody	  (and	  Treg	  cells	  fail	  to	  suppress	  this).	  	  
2. The	   autoantibodies	   are	   depicted	   in	   the	   bone	   marrow,	   affecting	  
megakaryocyte	  function.	  
3. Cytotoxic	  T	  cells	  are	  thought	  to	  play	  a	  role	  in	  platelet	  and	  megakaryocyte	  
destruction.	  	  
(Figure	   reproduced	   with	   permission	   from	   Kashiwagi,	   Tomiyana.	   Pathophysiology	   and	  
Management	  of	  Primary	  Immune	  Thrombocytopenia,	  published	  in	  Int	  J	  of	  Hematology	  2013	  
May	  24.	  See	  appendix	  2	  for	  permission)	  
	  	  
The	   primary	   problem	   in	   ITP	   is	   the	   risk	   of	   haemorrhage	   –	   most	   significantly	  
spontaneous	   haemorrhage	   that	   can	   lead	   to	   intracerebral	   bleeds	   or	   other	  
catastrophic	  bleeding.	  	  The	  risk	  of	  fatal	  bleeding	  is	  0.02	  to	  0.04	  cases	  per	  1000	  
patient-­‐years(16)	   and	   ITP	  has	   been	   associated	  with	   a	   risk	   of	   death	   that	   is	   four	  
times	   greater	   than	   that	   of	   the	   general	   population	   due	   to	   infection,	  
haematological	  malignancies	  and	  bleeding(17).	  Quality	  of	  life	  is	  lower	  than	  that	  of	  
the	  general	  population,	  predominately	  because	  of	  fatigue	  that	  is	  independent	  of	  
platelet	   count	   and	   not	   fully	   understood(17).	   	   A	   platelet	   count	   of	   greater	   than	  
30×109/L	  is	  the	  goal	  of	  treatment	  because	  patients	  with	  this	  platelet	  count	  have	  
been	   shown	   to	   have	   a	   long-­‐term	   mortality	   rate	   equal	   to	   that	   of	   the	   general	  
population(17).	  
	  
HIV	  associated	  thrombocytopenia	  
Thrombocytopenia	   is	   a	   common	   haematological	   abnormality	   in	   HIV	   and	   the	  
cause	   is	  multifactorial,	   including	  autoimmune	  destruction	  of	  platelets,	  reduced	  
platelet	   lifespan,	   and	   megakaryocyte	   dysfunction	   resulting	   in	   impaired	  
thrombopoesis.	  	  Thrombocytopenia	  is	  an	  important	  condition	  in	  HIV	  because	  of	  
the	  risk	  of	  haemorrhage	  and	  it	  has	  been	  shown	  to	  be	  associated	  with	  more	  rapid	  
disease	   progression	   to	   AIDS.	   	   Platelets	   engulf	   HIV	   virions	   and	   therefore	   are	  
thought	  to	  play	  a	  role	  in	  the	  immune	  response	  to	  HIV,(18)	  which	  partly	  explains	  
the	  association	  of	  thrombocytopenia	  with	  a	  high	  viral	  load(18,19,20).	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The	  prevalence	  of	  thrombocytopenia	  in	  HIV	  shows	  a	  bimodal	  distribution	  with	  a	  
peak	   in	  early	  HIV	  and	   then	  again	   in	  advanced	  HIV,	  but	  may	  occur	  at	  any	   time	  
during	   the	   course	  of	   the	   infection.	  Prior	   to	   the	  use	  of	   combined	  antiretroviral	  
therapy	  (cART),	  prevalence	  of	  ITP	  (platelet	  count	  <	  150×109/L)	  in	  HIV	  positive	  
patients	   was	   approximately	   11-­‐23%(21,22,23).	   	   Thrombocytopenia	   in	   the	   era	   of	  
cART	   is	  much	   lower,	  with	  one	   large	  study	  (of	  2298	  outpatients)	   reporting	   the	  
incidence	  at	  3.2%	  (20).	  	  
	  
In	   South	  Africa	   the	   prevalence	   of	   thrombocytopenia	   at	   enrolment	   for	   cART	   is	  	  
4%(24).	   	   It	   is	   interesting	   that	   in	   this	   study	   South	   Africa	   had	   a	   lower	   rate	   of	  
thrombocytopenia	  than	  India,	  Malawi,	  Brazil	  or	  the	  US	  (at	  enrolment	  for	  cART).	  	  
Factors	   that	  have	  been	  shown	   to	  be	  associated	  with	   thrombocytopenia	   in	  HIV	  
include:	   co-­‐infection	   with	   Hepatitis	   B	   and	   C	   (21,20);	   prevalence	   of	   drug	   use	  
(thrombocytopenia	   has	   been	   shown	   to	   be	   more	   severe	   in	   HIV-­‐infected	   drug	  
users)(19);	  and	  poor	  nutritional	  status	  (specifically	  selenium	  deficiency)(19).	  	  	  
	  
Early	   in	   the	   course	   of	   HIV	   infection,	   the	   predominant	   mechanism	   of	   ITP	   is	  
increased	   peripheral	   consumption	   due	   to	   autoantibodies.	   Multiple	   cross-­‐
reactive	   antibodies	   have	   been	   identified	   which	   ultimately	   result	   in	   increased	  
platelet	   destruction	   via	   Fcγ-­‐mediated	   phagocytosis	   by	   macrophages	   in	   the	  
reticuloendothelial	  tissues	  (especially	  the	  spleen),	  or	  complement-­‐independent	  
platelet	   fragmentation	   by	   the	   generation	   of	   hydrogen	   peroxide(25)	   .	   These	  
antibodies	   are	   directed	   at	   multiple	   epitopes,	   but	   include	   antibodies	   to	   HIV	  
glycoprotein120	   and	   the	   P24	   antigen	   that	   then	   cross-­‐react	   with	   glycoprotein	  
(GP)IIb	   and/or	  GPIIIa	   on	   platelets(18,26).	   	  More	   recently,	   an	   anti-­‐talin	   antibody	  
that	  attacks	  the	  cytoskeleton	  of	  the	  platelet	  has	  been	  identified	  in	  patients	  with	  
HIV	  and	  it	  has	  been	  proposed	  that	  this	  is	  the	  predominant	  antibody	  responsible	  
for	  platelet	  depletion	  (27).	  Talin	  cross-­‐links	  actin	  filaments	  and	  cytoplasmic	  tails	  
of	  beta	  integrins	  at	  focal	  adhesion	  points	  within	  platelets.	  Talin	  can	  be	  cleaved	  
during	   platelet	   activation	   and	   by	   HIV-­‐1	   protease	   and	   thus	   in	   HIV	   infection	  
becomes	  more	  readily	  exposed	  to	  the	  immune	  system.	  	  
	  
Late	   in	   HIV,	   the	   predominant	   cause	   of	   thrombocytopenia	   is	   inadequate	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thrombopoesis	   secondary	   to	   unmitigated	   cytokine	   release	   in	   the	   bone	  
marrow	   and	   direct	   infection	   of	   the	   megakaryocytes(28).	   Megakaryocytes	   bear	  
CD4+	   receptors	   capable	   of	   binding	  HIV-­‐1	   as	  well	   as	   the	   co-­‐receptor	  molecule	  
CXCR4(29,30)	   that	   enables	   HIV-­‐1	   entry	   into	   the	   megakaryocyte	   and	   results	   in	  
interference	  with	  normal	  platelet	  production.	  Patients	  with	  HIV-­‐associated	  ITP	  
have	  increased	  megakaryocyte	  mass	  as	  seen	  on	  bone	  marrow	  biopsy(31)	  as	  well	  
as	  an	  increase	  in	  thrombopoetin	  levels,(32)	  but	  this	  is	  inadequate	  to	  compensate	  
for	   the	   amplified	   peripheral	   consumption	   from	   an	   immune	   dysregulation	   and	  
dysmegakaryopoesis.	   On	   histological	   examination,	   megakaryocytes	   are	  
dysmorphic,	  with	  naked	  nuclei	  (apoptotic	  megakaryocytes),	  hypolobation	  of	  the	  
nuclei,	   tendency	   to	   form	   discrete	   nuclear	   lobules,	   and	   clustering	   of	   the	  
megakaryocytes(31).	  	  
	  
Late	   in	   HIV,	   there	   is	   increased	   susceptibility	   to	   intercurrent	   opportunistic	  
infections	   that	  may	   cause	   bone	  marrow	   suppression	   (in	   our	   setting	   TB	   is	   the	  
most	  important	  condition	  to	  exclude).	  
	  
It	  must	  be	  noted	  that	  the	  above	  discussion	  is	  likely	  an	  over-­‐simplification	  of	  the	  
pathogenesis	   in	   early	   and	   late	   HIV	   infection,	   since	   an	   imbalance	   of	   marrow	  
production,	  shortened	  platelet	  lifespan	  and	  immune	  destruction	  are	  present	  in	  
variable	  degrees	  throughout	  the	  course	  of	  HIV.	  	  
	  
2.)	  Treatment	  of	  ITP	  
 
Current	  practice	  is	  to	  initially	  treat	  ITP	  with	  high	  dose	  prednisone	  (1	  to	  2mg	  per	  
kg	  per	  day	  orally)	  for	  2	  to	  4	  weeks	  followed	  by	  tapering	  over	  a	  few	  weeks	  if	  the	  
platelet	  count	  responds.	  	  If	  the	  platelet	  count	  fails	  to	  respond	  to	  this,	  the	  patient	  
is	   given	   other	   immunosuppressive	   therapy	   including	   dexamethasone,	  
azathioprine	  and	  cyclophosphamide.	   If	   the	  platelet	  count	   is	  refractory	  to	  these	  
drugs	   	  and	  the	  patient	  urgently	  needs	  treatment	  (for	  example	  prior	  to	  surgery	  
or	  if	  the	  patient	  is	  bleeding),	  the	  patients	  are	  treated	  with	  plasmapheresis,	  IVIG	  
(intravenous	  immunoglobulins)	  and	  platelet	  transfusion(33).	  	  
	  
	   24	  
If	   the	   platelet	   count	   does	   not	   respond	   to	   steroid	   treatment	   or	   if	   the	   ITP	  
relapses	   after	   weaning	   steroid	   therapy	   	   (steroid	   dependence),	   the	   patient	  
should	   be	   considered	   for	   splenectomy,	   possibly	   with	   a	   trial	   of	   an	  
immunosuppressant	  such	  as	  azathioprine	  before	  surgery(33).	  
	  
Current	  practice	  for	  the	  management	  of	  ITP	  in	  HIV	  is	  antiretroviral	  therapy	  and	  
glucocorticoids.	   However,	   there	   is	   a	   paucity	   of	   data	   on	   the	   quality	   of	   the	  
response	   to	   steroids,	   the	   relapse	   rate	   and	   in	   particular,	   the	   longer-­‐term	  
outcome	   of	   these	   patients(21).	   	   There	   have	   been	   a	   few	   studies	   that	   have	  
demonstrated	   that	   splenectomy	   as	   a	   treatment	   for	   HIV-­‐ITP	   refractory	   to	  
medical	  therapy	  is	  safe	  and	  effective	  (to	  be	  discussed	  in	  more	  detail	  below)	  and	  
after	  initial	  concerns	  in	  the	  pre-­‐cART	  era	  that	  splenectomy	  caused	  a	  more	  rapid	  
progression	   to	   AIDS	   were	   dispelled(34),	   it	   has	   been	   a	   more	   commonly	   used	  
strategy.	   Treatment	   guidelines	   for	  HIV-­‐associated	   thrombocytopenia	   have	   not	  
yet	   been	   formalised	   because	   of	   a	   lack	   of	   high-­‐quality	   clinical	   trials.	   These	   are	  	  
therefore	  based	  on	   expert	   opinion,	   and	  have	   followed	   the	   treatment	  of	   ITP	   in	  
HIV	  negative	  patients(35).	  	  
 
Glucocorticoids	  
Corticosteroids	   are	   effective	   first	   line	   treatment	   in	   ITP	   and	   have	   several	  
mechanisms	   of	   action.	   They	   work	   by	   inhibiting	   the	   expression	   of	   splenic	  
macrophage	   Fc	   receptors,	   and	   thereby	   decrease	   the	   splenic	   destruction	   of	  
platelets.	   Steroids	   also	   inhibit	   the	   lymphoid	   clone	   that	   produces	   the	   auto-­‐
antibody	   directed	   against	   platelet	   membrane	   epitopes.	   However,	  
glucocorticoids	  at	  high	  doses	  have	  risks.	   In	  particular	  they	   increase	  the	  risk	  of	  
infection,	  especially	  tuberculosis	  in	  our	  patient	  population..	  	  
	  
Conventionally	  prednisone	  is	  used	  at	  a	  dose	  of	  1-­‐2mg/kg/day	  and	  can	  produce	  
an	   initial	   increase	   in	   the	   platelet	   count	   to	   over	   100×109/L	   in	   about	   80%	   of	  
patients(36),	   but	   the	   long	   term	   response	   is	  much	   lower	   and	  only	   a	  minority	   of	  
patients	   will	   maintain	   platelets	   above	   100×109/L	   after	   cessation	   of	  	  
therapy(36,37,38).	  	  	  There	  were	  no	  randomised	  controlled	  trials	  of	  steroids	  versus	  
placebo	   in	   the	   literature	   (likely	  because	   steroids	  have	   an	   established	  benefit).	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Three	   large	   cohort	   studies	   with	   heterogenous	   definitions	   of	   ‘complete	  
response’	  were	  reviewed;	  the	  results	  are	  included	  in	  Table	  1	  below.	  	  It	  should	  be	  
noted	  that	   ‘Complete	  response’	  by	  the	  definitions	  given	  	   is	  not	  the	  only	  goal	  of	  
therapy,	  as	  a	  platelet	  count	  of	  >30×109/L	  does	  not	  need	  further	  treatment	  (33).	  	  
Study	   Total	   no	  
pts	  
No	   of	   pts	  
on	  
steroids	  





Pamuk	  et	  al	   321	   129	   >100×109	  at	  3mo	   52%	   33	   58%	  
Li	  et	  al	   1791	   689	   >100×109	  (no	  time	  
period	  given)	  
30%	   36	   Not	  
included	  
Zimmer	   et	  
al	  




Table	  1.	  Response	  rate	  to	  glucocorticoid	  therapy.	  CR	  –	  complete	  response.	  
	  
High	  dose	  dexamethasone	  was	  shown	  to	  be	  effective	  in	  one	  study	  that	  included	  
125	   patients	   with	   ITP;	   almost	   40%	   had	   a	   sustained	   response	   that	   lasted	   2-­‐5	  
years(39).	  	  	  	  
 
Intravenous	  immunoglobulin	  and	  anti-­‐D	  immunoglobulin	  	  
Intravenous	   immunoglobulin	   produces	   a	   significant	   improvement	   in	   the	  
majority	   of	   patients	   with	   idiopathic	   and	   HIV	   associated	  
thrombocytopenia(40,41).The	  response	  is	  rapid,	  usually	  after	  one	  dose,	  however	  it	  
is	  typically	  transient,	  and	  so	  multiple	  costly	  infusions	  may	  be	  required,limiting	  
its	   use..	   The	  mechanism	   of	   action	   is	   saturation	   of	   Fc	   receptors	   in	   the	   spleen,	  
thereby	  preventing	  the	  removal	  of	  platelets.	   	   	  Its	  primary	  use	  is	  for	  emergency	  
management	  of	  ITP	  in	  settings	  of	  life-­‐threatening	  bleeding,	  or	  prior	  to	  surgery.	  	  
	  
Intravenous	  anti-­‐rhesus	   immunoglobulin	   is	  a	  solution	  of	   IgG	  anti-­‐D	  (anti-­‐RhD)	  
antibodies,	   it	  has	  a	   	  similar	  response	  rate	   to	   IVIG(42),	  at	   less	  cost.	  However	   the	  
concern	  is	  that	  it	  can	  lead	  to	  haemolysis	  and	  for	  this	  reason	  it	  can	  only	  be	  given	  
to	  patients	  with	  an	  adequate	  haemoglobin	  level,	  and	  who	  are	  Rhesus	  positive.	  	  It	  
increases	  platelet	  counts	  in	  the	  short	  term	  but	  does	  not	  have	  a	  durable	  effect(43).	  
It	  works	  by	   the	  competitive	  binding	  of	  Fc	  receptors	   in	   the	  spleen:	  Rh-­‐	  antigen	  
binds	   to	   the	   red	   cell	  membrane	   and	   these	   sensitised	  RBCs	   are	   cleared	   by	   the	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spleenwith	  consequent	  reduction	   in	  platelet	  clearance.	   	   In	  South	  Africa	  only	  
the	  intramuscular	  form	  of	  anti	  –D	  is	  available.	  	  
	  
Azathioprine	  and	  Cyclophosphamide	  
In	   their	   consensus	   document,	   Provan	   et	   al	   recommended	   azathioprine,	  
cyclophosphamide	   and	   other	   immunosuppressive	   therapies	   (mycophenolate	  
mofetil,	   cyclosporin,	   vincristine)	   to	   be	   used	   as	   second-­‐line	   agents	   prior	   to	  
splenectomy(44).	   	   However,	   the	   most	   recent	   guidelines	   from	   the	   American	  
Society	  of	  Hematology	  have	  not	  recommended	  included	  these	  drugs	  because	  of	  
considerable	  variability	  in	  individual	  responses	  and	  toxicity,	  including	  immune	  
suppression,	  hepatic	  toxicity	  and	  secondary	  malignancies(33).	  	  
	  
 
Danazol	  and	  Dapsone	  
Danazol	  (an	  attenuated	  androgen)	  has	  been	  used	  to	  treat	  ITP	  with	  mixed	  results	  	  
–	   its	  overall	  efficacy	  has	  been	  shown	  to	  be	  quite	  unsatisfactory	  in	  HIV	  positive	  
patients(45).	  	  
	  
Dapsone	   is	   thought	   to	   act	  by	  a	   competitive	   effect	  on	   red	   cell	   clearance	  by	   the	  
reticuloendothelial	  system.	  Very	  small	  studies	  have	  tested	  dapsone’s	  efficacy	  in	  
ITP(46,47),	  and	  they	  have	  shown	  some	  success.	  	  
 
Antiretroviral	  agents	  for	  HIV	  associated	  thrombocytopenia	  
Antiretroviral	   agents	  work	   to	   raise	   the	  platelet	   count	  primarily	   by	  decreasing	  
the	  HIV	   viral	   load	   burden,	   but	   this	   is	   unlikely	   the	   comprehensive	  mechanism	  
since	  certain	  antiretrovirals	  are	  more	  effective	  than	  others.	  In	  the	  years	  before	  
cART	   numerous	   studies	   demonstrated	   that	   zidovudine	   monotherapy	   was	  
efficacious	  in	  increasing	  the	  platelet	  count	  (48-­‐52).	  	  
	  
In	  one	  study	  comparing	  cART	  to	  AZT	  monotherapy	  response	  rates	  to	  cART	  were	  
found	   to	  be	  similar.	  Combination	  antiretroviral	   therapy	  was	   found	   to	   increase	  
the	   platelet	   count	   to	   above	   50	   x109/L	   in	   73%	   of	   patients,	   with	   a	   complete	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response	   (increase	   of	   platelets	   >	   100×109/L)	   in	   53%	   of	   patients;	   this	  
response	  occurred	  within	  the	  first	  three	  months	  of	  treatment	  and	  was	  sustained	  
throughout	  the	  treatment	  period	  (53).	  	  
	  
In	  practice	   it	   is	  preferable	   to	  use	  cART	  over	  AZT	  monotherapy	  because	  of	   the	  
risk	   of	   HIV	   resistant	   strains	   being	   selected	   with	   monotherapy.	  
Thrombocytopenia	   is	   therefore	   an	   indication	   to	   start	   cART,	   and	   based	   on	   the	  
study	  above(53)	  the	  regime	  need	  not	  contain	  AZT	  (a	  drug	  that	  is	  associated	  with	  
significant	   side	   effects	   including	   bone	   marrow	   suppression	   and	   a	   high	  
frequency	  of	  gastrointestinal	  complaints).	  	  
	  
Rituximab	  
Rituximab	   is	   a	   monoclonal	   antibody	   against	   B-­‐cells	   that	   targets	   CD20.	  	  
Rituximab	   is	   used	   for	   the	   treatment	   of	   B-­‐cell	   lymphoid	   malignancies	   and	  
autoimmune	  conditions	   such	  as	   rheumatoid	  arthritis.	   	  Recently,	   rituximab	  has	  
been	   added	   to	   the	   armamentarium	   to	   treat	   ITP,	   but	   it	   has	   not	   been	   studied	  
systematically	   in	   HIV-­‐associated	   thrombocytopenia.	   In	   ITP	   its	   mechanism	   of	  
action	  is	  thought	  to	  be	  due	  to	  B	  cell	  depletion,	  however	  B	  cell	  depletion	  occurs	  
in	  all	  patients	  whereas	  a	  clinical	   response	  does	  not.	   	  Furthermore,	   the	   time	   to	  
clinical	   response	   (an	   increase	   in	   platelet	   count)	   is	   often	   irrespective	   of	  
immunoglobulin	   levels.	   Therefore,	   other	   mechanisms	   have	   been	   proposed	  
including	   Fc	   receptor	   saturation	   in	   the	   spleen	  with	   resultant	   inability	   to	   bind	  
platelets(54)	  and	  an	   increase	   in	  activity	  of	  T-­‐cell	   regulatory	  cells(55).	   In	  a	  recent	  
meta-­‐analysis	   the	   rate	   of	   long-­‐term	   complete	   response	   was	   20%,	   with	   an	  
overall	   response	   rate	   of	   57%	   (increase	   in	   platelet	   count	   to	   >100×109/L,	   but	  
with	  a	  mean	  duration	  of	  response	  of	  43	  weeks)(55).	  Currently	  it	  is	  beingutilised	  
in	  heavily	  treated	  patients,	  in	  the	  setting	  where	  either	  splenectomy	  has	  failed	  or	  
the	  patient	  has	  a	  contraindication	  to	  splenectomy.	  
	  
Rituximab	   is	   generally	   safe,	   however	   it	   depletes	   antibody-­‐producing	  
lymphocytes	  therefore	  makingpatients	  more	  susceptible	  to	  infection,	  and	  its	  use	  
is	   limited	   by	   high	   cost.	   A	   rare	   reported	   side	   effect	   is	   progressive	   multifocal	  
leukoencephalopathy	  caused	  by	  reactivation	  of	  latent	  JC	  virus,	  but	  the	  strength	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of	   association	   is	   weak	   as	   there	   are	   only	   a	   few	   case	   reports.	   	   The	   2011	  
American	  Society	  of	  Hematology	   (ASH)	   treatment	   guidelines	   gave	   rituximab	  a	  
weak	   recommendation	   (grade	   2C)	   for	   patients	  who	   have	   failed	   steroids,	   IVIG	  
and	  splenectomy(33).	  
	  
Thrombopoetin	  receptor	  agonists	  
Thrombopoetin	  (TPO)	  is	  the	  primary	  cytokine	  that	  regulates	  platelet	  production	  
and	   is	   produced	   by	   the	   liver	   and	   kidneys.	   TPO	   binds	   to	   the	   c-­‐Mpl	  
(myeloproliferative	   leukaemia	   virus	   oncogene)	   receptor	   to	   activate	   the	   JAK2	  
tyrosine	   kinase	   pathway	   dependent	   genes.	   This	   stimulates	   megakaryopoesis	  
which	   increases	   the	   number	   of	   platelets	   produced.	   	   The	   production	   of	  
thrombopoetin	  is	  fairly	  constant	  and	  yet	  the	  levels	  vary	  according	  to	  the	  platelet	  
count.	  The	  mechanism	  of	  this	  is	  thought	  to	  be	  that	  platelets	  and	  megakaryocytes	  
bind	  free	  TPO	  and	  degrade	  it,	  so	  the	  higher	  the	  platelet	  mass	  the	  lower	  the	  level	  
of	  thrombopoetin.	  
	  
TPO	   receptor	   agonists	  work	  by	   stimulating	   the	   c-­‐Mpl	   receptor.	   	   The	   first	  TPO	  
receptor	  agonists	   caused	  a	   cross-­‐reactive	  autoantibody	  and	   resulted	   in	   severe	  
thrombocytopenia	   in	  healthy	  study	  subjects.	   	   Second	  generation	  TPO	  receptor	  
agonists	   (such	   as	   romiplostim	   and	   eltrombopag)	   have	   no	   homology	   to	  
endogenous	  TPO	  and	  do	  not	   have	   this	   effect.	   These	  drugs	  have	  demonstrated	  
durable	  response	  rates	  (platelet	  count	  more	  than	  100×109/L	  at	  6	  to	  8	  weeks)	  in	  
50	   to	   60%	   of	   patients	   as	   long	   as	   treatment	   is	   maintained(56,57)	   and	   were	  
associated	   with	   fewer	   treatment	   failures,	   fewer	   splenectomies,	   less	   bleeding	  
and	  a	  better	  quality	  of	  life(58).	  	  However,	  in	  a	  large	  Cochcrane	  systematic	  review	  
neither	   TPO	   agonist	   improved	   the	   rate	   of	   severe,	   life-­‐threatening	   or	   fatal	  
bleeding(59)	   	   In	   addition,	   eltrombopag	   has	   shown	   to	   increase	   alanine	  
aminotransferase	  and	  indirect	  bilirubin	  concentrations	  and	  these	  levels	  need	  to	  
be	  monitored	  on	  treatment.	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3.)	  Splenectomy	  for	  ITP	  
	  
The	  spleen	  has	  a	  major	  role	  to	  play	  in	  immunity:	  it	  is	  largely	  responsible	  for	  the	  
effective	  clearance	  of	  encapsulated	  bacteria	  (opsonised	  bacteria	  are	  removed	  by	  
splenic	   macrophages)	   and	   production	   of	   antibody	   (IgM	   memory	   B	   cells	  
originate	   in	   the	   splenic	  marginal	   zone	   in	   response	   to	   antigen	   and	   activated	  T	  
cells).	  It	  also	  has	  an	  anti-­‐inflammatory	  function,	  having	  been	  shown	  to	  dampen	  
down	   the	   cytokine	   response(63,64),	   which	   when	   unchecked	   has	   deleterious	  
effects	  in	  sepsis.	  
	  
In	  the	  management	  of	  ITP	  splenectomy	  is	  reserved	  for	  those	  patients	  who	  have	  
failed	  medical	   therapy.	   In	  our	   setting,	   it	   is	  utilised	   for	  patients	  who	  are	  either	  
resistant	   to	   steroids	   (platelet	   count	   does	   not	   increase	   to	   >50×109/L	   despite	  
prednisone	   at	   a	   dose	   of	   1-­‐2mg/kg)	   or	   in	   patients	  who	   are	   steroid-­‐dependent	  
(relapse	  off	  treatment).	  
	  
Splenectomy	   has	   been	   shown	   to	   be	   both	   relatively	   safe	   in	   ITP,	   as	   well	   as	  
effective(60).	  In	  a	  large	  systematic	  review	  published	  in	  2004,	  complete	  response	  
following	  splenectomy	  was	  reported	  to	  reach	  60%(60).	  	  Here,	  complete	  response	  
was	   defined	   as	   achievement	   and	   maintenance	   of	   a	   normal	   platelet	   count	  
(150×109/L)	  for	  all	  measurements	  for	  30	  days	  or	  longer	  after	  splenectomy	  with	  
no	   additional	   treatment	   for	   ITP.	   However,	   a	   difficulty	   when	   reviewing	   these	  
articles	   is	   that	   ‘complete	   response’	   is	   defined	   differently:	   some	   studies	   use	  
platelet	  count	  at	  one	  month	  to	  determine	  response,	  but	  we	  know	  that	  patients	  
can	   relapse	   later	   therefore	   uncertainty	   remains	   as	   to	   the	   durability	   of	  
splenectomy	  for	  ITP.	  	  
	  
The	  mortality	  rate	  of	  splenectomy	  has	  been	  reported	  to	  be	  0.2%	  and	  1.0%	  for	  
laparoscopy	  and	  open	  laparotomy,	  respectively(60).	  Mortality	  was	  primarily	  due	  
to	   bleeding,	   sepsis	   (pneumonias	   and	   subdiaphragmatic	   or	   splenic	   bed	  
abscesses)	  and	  venous	  thromboembolism.	  Complication	  rates	  were	  12.9%	  (318	  
of	   2465	   patients)	   with	   laparotomy	   and	   9.6%	   (88	   of	   921	   patients)	   with	  
	   30	  
laparoscopic	  splenectomy.	  A	  well	  recognised	  complication	  of	  splenectomy	  is	  
postsplenectomy	   sepsis	   (PSS)	   or	   overwhelming	   post-­‐splenectomy	   infection	  
(OPSI).	  OPSI	   occurs	   at	   an	   estimated	   incidence	   of	   0.23–0.42%	  per	   year,	  with	   a	  
lifetime	   risk	   of	   5%	   (61).	   	   Ithas	   a	   short	   prodrome	   with	   low-­‐grade	   fever,	   chills,	  
pharyngitis,	   muscle	   aches	   and	   often	   vomiting	   or	   diarrhoea.	   	   Deterioration	   is	  
abrupt,	  often	  within	  hours,	  and	  the	  mortality	  rate	  is	  50-­‐70%	  despite	  antibiotics	  
and	   intensive	   support(62).	   	   In	   a	   large	   review	  of	  12514	  patients,	  pneumococcus	  
was	  the	  leading	  cause	  of	  sepsis	  (in	  50-­‐90%	  of	  cases),	  followed	  by	  Haemophilus	  
influenzae,	  then	  meningococcus(62).	  
	  
There	   are	   recommendations	   for	   reducing	   the	   risk	   of	   PSS	   including	  
immunization	   against	   common	   or	   dangerous	   organisms,	   and	   possibly	  
prophylactic	   antibiotics.	   	   It	   is	   recommended	   that	   all	   patients	   receive	   the	  
pneumococcal	  vaccine	  two	  weeks	  prior	  to	  splenectomy.	  In	  HIV	  negative	  patients	  
either	  the	  23-­‐	  or	  the	  7-­‐valent	  vaccine	  is	  recommended(62).	  	  The	  7-­‐valent	  vaccine	  
is	  more	   immunogenic	  and	  does	  not	  require	  a	  booster.	   In	  HIV	  positive	  patients	  
the	  23	  valent	  vaccine	  (Pneumovax)	  has	  been	  shown	  to	  have	  an	  increased	  rate	  of	  
pneumonic	  events(65),	   so	   is	   to	  be	  avoided	   in	  HIV,	  while	   the	  7-­‐valent	  vaccine	   is	  
protective	  against	  pneumococcus	  (66).	  	  Other	  recommended	  vaccines	  include	  an	  
annual	   influenza	  vaccine,	  a	  single	  Haemophilus	   infleunzae	  vaccine	  (considered	  
immunogenic	  in	  asplenic	  individuals)	  and	  the	  meningococcal	  vaccine.	  	  Although	  
meningococcus	  does	  not	  play	  a	  large	  role	  in	  OPSI,	  given	  the	  severity	  of	  infection	  
if	  it	  does	  occur	  it	  is	  recommended	  to	  give	  the	  vaccine.	  
	  
There	  is	  no	  clear	  consensus	  regarding	  the	  use	  of	  prophylactic	  antibiotics	  as	  the	  
potential	   benefit	   is	   balanced	   by	   poor	   adherence	   to	   treatment	   as	   well	   as	   the	  
potential	   to	   select	   out	   resistant	   strains.	   It	   is	   not	   recommended	   following	  
splenectomy	   for	   ITP	   and	   no	   research	   has	   been	   done	   to	   look	   at	   this	   in	   HIV-­‐
infected	   individuals.	   	   The	   practice	   at	   Groote	   Schuur	   Hospital	   over	   the	   study	  
period	  was	  not	  to	  use	  prophylactic	  antibiotics.	  
	  
Initial	  concerns	  that	  splenectomy	  hastened	  the	  development	  of	  AIDS	  have	  been	  
dispelled,	   and	   splenectomy	   in	   HIV-­‐ITP	   has	   been	   shown	   to	   be	   both	   safe	   and	  
effective(34).	   Oksenhendler	   et	   al	   reported	   long-­‐term	   experience	   in	   a	   cohort	   of	  
	   31	  
185	   patients	   with	   HIV-­‐ITP(34).	   Splenectomy	   was	   performed	   in	   68	   of	   these	  
patients,	   at	   an	   average	   of	   13	   months	   from	   initial	   diagnosis	   of	   HIV-­‐ITP.	   A	  
response	  was	  seen	  in	  92%	  of	  patients	  and	  maintenance	  of	  the	  elevated	  platelet	  
count	   for	   longer	   than	   6	   months	   was	   documented	   in	   82%	   of	   splenectomised	  
patients.	  	  
	  
In	   the	  Oksenhendler	   series	   (in	  HIV)	  5.8%	  of	  patients	  undergoing	   splenectomy	  
experienced	   fulminant	   infection,	   consisting	   of	   Streptococcus	   pneumoniae	  
meningitis	  in	  two	  and	  Haemophilus	  influenzae	  sepsis	  in	  one	  individual(34).	  	  	  	  
	  
Splenectomy	   is	   therefore	   efficacious	   and	   safe	   for	   the	  majority	   of	   patients	   but	  
carries	  a	  risk	  of	  increased	  susceptibility	  to	  infections	  as	  well	  as	  operative	  risks,	  
and	  is	  therefore	  only	  used	  after	  medical	  treatment	  has	  failed.	  	  
 
LITERATURE	  REVIEW	  CONCLUSIONS	  
After	  a	  review	  of	  the	  literature,	  it	  is	  evident	  that	  there	  is	  a	  wealth	  of	  information	  
on	   the	   pathogenesis	   and	   pathophysiology	   of	   ITP,	   and	   treatment	   of	   ITP.	   	   	   The	  
areas	   that	   have	   not	   been	   well	   studied	   are:	   the	   long-­‐term	   outcomes	   of	  
splenectomy	   for	   ITP	   (with	   most	   studies	   only	   including	   a	   month	   of	   follow-­‐up	  
time(60)),	   and	   	   larger	   studies	   are	   needed	   on	   splenectomy	   for	   ITP	   in	   HIV	  	  
particularly	  in	  a	  third-­‐world	  setting.	  	  
	  
There	  are	  new	  agents	   that	  have	  been	  proposed	  as	  second-­‐line	   therapy	   for	   ITP	  
(namely	   ritixumab	   and	   TPO	   agonists)	   and	   it	   has	   therefore	   become	   more	  
relevant	  to	  quantify	  the	  risks	  of	  splenectomy	  as	  well	  as	  the	  treatment	  response	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Summary:	  	  
Background	  
Splenectomy	  is	  indicated	  in	  immune	  thrombocytopaenic	  purpura	  (ITP)	  when	  a	  
patient	  is	  either	  dependent	  or	  resistant	  to	  steroid	  treatment	  (platelet	  count	  
<30×109/L).	  	  New	  agents	  are	  being	  developed	  to	  treat	  ITP,	  and	  have	  brought	  
into	  question	  the	  relevance	  of	  splenectomy.	  	  Of	  particular	  interest	  in	  our	  context	  
is	  the	  role	  of	  splenectomy	  in	  ITP	  patients	  with	  HIV	  infection.	  
Methods	  
In	  this	  retrospective	  study,	  consecutive	  patients	  who	  had	  undergone	  
splenectomy	  in	  the	  period	  2001-­‐2011	  were	  identified.	  Follow-­‐up	  period	  platelet	  
counts	  and	  outcomes	  were	  reviewed,	  and	  compared	  in	  HIV	  negative	  and	  
positive	  patients.	  	  
Results	  
Seventy-­‐three	  patients	  were	  included	  in	  the	  study,	  12	  were	  HIV	  positive.	  
Splenectomy	  was	  laparoscopic	  in	  43	  (62%)	  and	  by	  laparotomy	  in	  27	  patients	  
(38%)	  with	  an	  overall	  16%	  complication	  rate.	  Complete	  response	  rate	  was	  80%	  
(CI	  69-­‐91%).	  	  	  The	  90-­‐day	  mortality	  rate	  was	  1.38%.	  	  Seven	  patients	  died	  in	  the	  
follow	  up	  period.	  There	  was	  no	  statistically	  significant	  difference	  in	  response	  
rates	  or	  proportion	  of	  complications	  in	  the	  HIV	  positive	  patients.	  
Conclusion	  
Splenectomy	  is	  effective	  and	  safe	  irrespective	  of	  HIV	  status	  and	  remains	  an	  
appropriate	  second-­‐line	  treatment,	  with	  the	  newer	  therapies	  reserved	  for	  cases	  
refractory	  to	  splenectomy	  or	  when	  surgery	  is	  contraindicated.	  
Keywords:	  
Splenectomy;	  ITP	  (immune	  thrombocytopenia);	  HIV	  (human	  immunodeficiency	  
virus);	  Platelets;	  South	  Africa	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Introduction	  	  
Splenectomy	  has	  been	  practiced	  as	  treatment	  of	  ITP	  for	  the	  past	  few	  decades;	  
currently	  it	  is	  utilised	  when	  a	  patient	  is	  either	  dependent	  or	  resistant	  to	  steroid	  
treatment	  and	  the	  platelet	  count	  remains	  <30×109/L(1).	  	  Recently,	  new	  agents	  
have	  been	  added	  to	  the	  current	  armamentarium	  used	  to	  treat	  ITP;	  including	  
immunosuppressants	  such	  as	  rituximab	  and	  the	  new	  thrombopoetin-­‐receptor	  
agonists.	  	  This	  has	  brought	  into	  question	  the	  role	  of	  surgery	  for	  the	  treatment	  of	  
ITP,	  and	  the	  need	  to	  compare	  the	  response	  and	  complication	  rates	  of	  
splenectomy	  to	  these	  newer	  agents.	  	  As	  a	  result,	  treatment	  of	  patients	  with	  ITP	  
who	  fail	  first-­‐line	  therapy	  is	  controversial(2),	  and	  the	  decision	  of	  whether	  to	  try	  
further	  medical	  therapy	  or	  splenectomy	  should	  be	  based	  on	  efficacy	  and	  side-­‐
effect	  profile	  of	  the	  agents	  (including	  the	  operative	  morbidity	  and	  mortality),	  
patient	  fitness	  for	  surgery	  and	  co-­‐morbidities	  as	  well	  as	  patient	  preference	  and	  
cost.	  	  Splenectomy	  has	  perioperative	  and	  long-­‐term	  risks	  ,	  including	  mortality	  
(3,4),	  but	  it	  offers	  the	  possibility	  of	  cure	  in	  the	  majority	  of	  patients(3,5,6).	  However,	  
newer	  treatments	  may	  potentially	  allow	  splenectomy	  to	  be	  deferred	  for	  
prolonged	  periods,	  as	  well	  as	  providing	  alternative	  treatment	  options	  for	  
patients	  who	  fail	  splenectomy.	  
Historic	  studies	  done	  on	  patients	  undergoing	  splenectomy	  for	  the	  treatment	  of	  
ITP	  have	  been	  performed	  in	  setting	  of	  low	  prevalence	  of	  HIV.	  There	  is	  a	  relative	  
paucity	  of	  data	  on	  the	  response	  rate	  in	  HIV-­‐associated	  thrombocytopenia	  with	  
splenectomy	  and	  the	  durability	  of	  response	  to	  splenectomy	  has	  yet	  to	  be	  
established	  in	  this	  patient	  population.	  
Methods	  
Ethical	  Approval	  
Approval was obtained by the UCT ethics committee (approval no. 437/2012); 
see ethics approval attached as appendix 1.  
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Patient	  Selection	  
Seventy-three consecutive patients who had undergone splenectomy for ITP in 
the time period of 2001 – 2011, were retrospectively identified.  ITP was confirmed 
as the diagnosis using the American Society of Haematology Guidelines(1): patients 
with an isolated thrombocytopenia platelets <100 ×109/L (anaemia only if significant 
bleeding related to thrombocytopenia), platelets on smear of normal to large in size 
while the bone marrow biopsy was not required for diagnosis.  Patients with primary 
ITP, as well as patients with secondary ITP due to HIV, Hepatitis and connective 
tissue disease were included.  Patients with lymphoproliferative disease were not 
included.  
These patients were identified using both the histology records (all patients who 
undergo splenectomy for medical indications have the spleen sent for histology at 
Groote Schuur) at the National Health Laboratory System (NHLS) and the surgical 
records (the operative notes) held by the department of surgery at Groote Schuur 
Hospital.  Although the protocol required that the excised spleens from patients 
undergoing splenectomy was referred for histological examination (except in trauma 
cases), this may not always have been done which may have created selection bias. 
Clinical	  Information	  
Patients’ folders were obtained both from the haematology records (the 
haematology ‘buffs’), and the Groote Schuur folders.  If necessary, the microfilmed 
folders were also reviewed.   
The medical records of these patients were reviewed for the clinical and 
laboratory information regarding their diagnosis and management:  
1. Initial treatment: patients included in the study were often either treated at 
peripheral hospitals with prednisone and referred to GSH after 
unsuccessful weaning or failing therapy outright, or were attending the 
GSH Haemtalogy clinic from diagnosis. After patients were confirmed as 
being steroid dependent or steroid resistant at GSH they were evaluated 
for splenectomy as second line management. 
2. Co-morbidites.  
3. Laboratory results for HIV, anti-nuclear  antibody, hepatitis B surface 
antigen, renal function and spleen histology results. These results were 
obtained from the NHLS’ online system which includes laboratory 
records from any public hospital in the Western Cape Where the results 
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were not available from the NHLS (prior to 2003) the information was 
obtained from the folders. 
4. Specific pre-operative medical management including platelet 
transfusions, plasmaphersis or IVIG.  
5. Operative notes: type of splenectomy performed (open versus 
laparoscopic), intra-operative difficulties or complications. Patients either 
underwent laparoscopic or open splenectomy - the choice of technique 
depended predominately on the time period during which the operation 
was performed.  More patients  had open surgery early in the study period 
(before 2004) and the reverse in the latter period. Certain patients were 
precluded from laparoscopic surgery on the basis of expected difficulties, 
for example obesity or previous laparotomy with possible adhesions.   
The reasons for open splenectomy were recorded. 
6. Post-operative details: complications, length of hospital stay 
7. Post-operative clinic follow-up: later complications 
8. In the case of the HIV positive patients: CD4 count at diagnosis of ITP or 
at referral to GSH and anti-retroviral treatment received.  
9. The platelet counts at 1 month, 6 months and 1 year were recorded 
(within 2 weeks of the exact date).  If the platelet count was not available 
for one year exactly, but there was a count from after one year, then the 
platelet count nearest this date was recorded. 
10. The entire set of platelet counts was reviewed following splenectomy for 
the duration of patient follow-up, and if there was a platelet count of less 
than 100 ×109/L this result was recorded and the medical management of 
the relapse was reviewed. 
11. For survival data, the patient’s last GSH visit and latest blood test results 
were considered.  Whichever of these was most recent was taken to be the 
date the patient was last definitely known to have been alive.  
 
 The relevant blood and histology results on these patients were obtained from 
the NHLS, using both the online system, which can access results of blood tests 
taken at any public hospital in the Western Cape, and the Groote Schuur blood 
results.  Where the blood results were not available from either of these two systems, 
the information was obtained from the folder. 
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Definitions	  of	  response	  to	  medical	  treatment	  
All patients were initially treated with oral corticosteroids and were recorded as 
being either steroid dependent or steroid-resistant.  
1. Steroid dependence was defined as a platelet count dropping to less than 
100×109/L within 6 months from weaning off steroids. 
2. Steroid resistance was defined as a platelet count never recorded at greater 
than 100×109/L despite corticosteroids at 2mg/kg/day.    
Definitions	  of	  response	  to	  splenectomy	  	  
Platelet counts post-splenectomy were recorded at one month, six months, and one 
year but all available results were examined and if there was a result <100×109/L this 
was specifically recorded.  Due to heterogeneity in study definitions of response in 
the literature, as well as the longer duration of our study, we defined response rates 
as follows:  
1. Complete response was defined as a platelet count greater than 100×109/L, 
maintained for at least a year as the latest follow-up, or until the most recent 
if contact was maintained for longer than a year, without the patient receiving 
further immunosuppression (other than being weaned off steroids in 1 month 
to 6 weeks post-operative period).   
2. No response: the platelet count never increased to >30×109/L in the first year post 
splenectomy. 
3. Partial response was defined as patients who achieved a platelet count of 30-
100×109/L in the year post splenectomy.   
 
Patients were offered immunisation against pneumococcal and haemophilus 
influenza infections 2 weeks prior to splenectomy; this was not specifically audited 
except if a patient developed post-splenectomy sepsis.  
Definition	  of	  Hepatitis	  B	  positive	  and	  ANA	  positive	  
Patients were regarded as having chronic Hepatitis B if the surface antigen was 
positive or if there was a recorded viral load on the NHLS system.  Over the time 
period of the study, the laboratory reference range for anti-nuclear antibody (ANA) 
changed and so the patient was reported as positive if the result was above the 
reference range given. 
 
	   44	  
Statistics	  
Microsoft Excel 2010 (Microsoft Corporation, Washington, USA) was used for 
database and data input. Statistical analyses were performed using STATA statistical 
software, version 12.0 (STATA Corporation, College Station, Texas, USA). 
Descriptive characteristics of the patients were analysed, mean ± standard deviation 
was used for normally distributed data and median plus interquartile ranges for non-
normally distributed data.  Survival analysis was based on the Kaplan-Meier estimate 
and the log-rank test was used for survival comparisons between the HIV negative 
and HIV positive groups.  To assess the association between HIV status and 
complete response the prevalence ratio was calculated (since the prevalence of the 
‘complete response’ was >10% and in this situation odds ratios overestimate the 
magnitude of risk(7). Continuous and categorical variables were compared using chi2, 
and when the expected frequencies in any cell of the contingency tables was <5 the 
Fishers exact test was used. All P-values were considered significant at P≤ 0.05.  To 
compare means if the data was normally distributed (tested by doing a Shapiro Wilk 
test) then a t-test was performed; if the data were not normally distributed then a 
Wilconxon-Mann-Whitney test was performed. 
Results	  
1. Patient	  characteristics	  
The	  median	  age	  at	  splenectomy	  was	  33	  years	  (range:	  16-­‐70	  years).	  	  	  	  There	  was	  
a	  female	  preponderance	  with	  a	  ratio	  of	  3:1,	  56	  patients	  (77%)	  were	  female	  17	  
patients	   were	   male	   (23%).	   Of	   the	   58	   patients	   for	   whom	   the	   HIV	   status	   was	  
known,	  12	  were	  HIV	  positive	  (21%),	  and	  46	  were	  HIV	  negative	  (79%).	   	  Of	  the	  
36	  patients	  for	  whom	  the	  Hepatitis	  B	  status	  were	  known;	  5	  were	  positive	  (14%)	  
and	  31	  were	  negative	  (86%).	  	  Of	  the	  39	  patients	  for	  whom	  the	  ANA	  status	  was	  
known,	   19	   patients	   (49%)	   were	   ANA	   positive	   and	   	   20	   (51%)	   were	   negative.	  	  
Eight	   (11%)	   of	   the	   patients	   had	   diabetes,	   9	   (12%)	   had	   Systemic	   Lupus	  
Erythematosis	  (SLE)	  	  and	  10	  (14%)	  had	  Tuberculosis	  (TB)	  which	  was	  diagnosed	  
within	  6	  months	  before	  or	  after	   the	  diagnosis	  of	   ITP.	   	  One	  patient	  had	  proven	  
Helicobacter	   pylori	   gastritis	   at	   the	   time	   of	   diagnosis	   of	   ITP,	   three	   had	  
hypothyroidism	  and	  two	  likely	  had	  syphilis	  (positive	  RPR	  titres).	  Two	  patients	  
were	   pregnant	   at	   the	   time	   of	   diagnosis	   of	   ITP,	   and	   one	   patient	   underwent	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splenectomy	   while	   pregnant.	   See	   Table	   1	   for	   patient	   characteristics	   at	  
diagnosis.	  
Table	  1.	  	  Patient	  characteristics	  at	  diagnosis	  
Variables	   N=73	   %	  
Age	  (yrs),	  median	  (range)	   33	  (16-­‐70)	   	  
Gender	   	   	  
Male	   17	   23	  
Female	   56	   77	  
HIV	  status	   	   	  
Positive	   12	   16	  
Negative	   46	   63	  
Unknown	   15	   21	  
Hepatitis	  B	  status	   	   	  
Positive	   5	   7	  
Negative	   31	   42	  
Unknown	   37	   51	  
ANA	   	   	  
Positive	   19	   26	  
Negative	   20	   27	  
Unknown	   34	   47	  
Co-­morbidities	   	   	  
Diabetes	   8	   11	  
SLE	   9	   12	  
TB	   10	   14	  
	  
2. Medical	  treatment	  prior	  to	  splenectomy	  
Of	  the	  patients	  for	  whom	  details	  regarding	  treatment	  prior	  to	  splenectomy	  were	  
available	   (n=69);	   37	   (54%)	   were	   steroid-­‐dependent,	   and	   32	   (46%)	   were	  
steroid-­‐resistant.	  	  Corticosteroids	  (oral	  prednisone)	  were	  given	  to	  all	  patients	  at	  
a	  dose	  of	  1-­‐2mg/kg/day.	  	  Azathioprine	  was	  given	  to	  23	  patients	  (33%);	  the	  less	  
frequently	   used	  medical	   treatments	  were:	   polyvalent	   human	   immunoglobulin	  
(‘Polygam’:	   Natal	   Bio	   Products)	   (n=6);	   intravenous	   dexamethasone	   to	   (n=5),	  
plasmapheresis	  (n=5);	  cyclophosphamide	  (n=2);	  dapsone	  (n=1);	  danazol	  (n=1);	  
splenic	  radiation	  (n=1).	  See	  table	  2	  for	  initial	  treatment.	  
Table	  2.	  	  Response	  to	  initial	  therapy	  
Response	  to	  oral	  steroids	  (n=69)	   	   	  
Steroid	  dependent	   37	   54	  
Steroid	  resistant	   32	   46	  
Treatment	  (n=69)	   	   	  
Prednisone	   69	   100	  
Azathioprine	   23	   33	  
Polygam	   6	   9	  
IVI	  dexamethasone	   5	   7	  
Plasmapheresis	   5	   7	  
Cyclophosphamide	   2	   3	  
Dapsone	   1	   1	  
Danazol	   1	   1	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3. HIV	  positive	  population	  
Of	  the	  12	  patients	  who	  were	  HIV	  positive,	  7	  were	  female	  and	  5	  male.	  In	  the	  HIV	  
positive	  population	   the	  median	  age	  was	  36	  (range:	  26-­‐55	  years).	   	  The	  median	  
CD4	  count	  (in	  cells/mm3)	  at	  diagnosis	  of	  ITP	  was	  253	  (range	  52-­‐1798):	  7	  (70%)	  
of	  patients	  had	  CD4	  counts	  less	  than	  300	  cells/mm3,	  2	  had	  CD4	  counts	  greater	  
than	   700	   cells/mm3,	   and	   1	   patient	   had	   a	   CD4	   count	   between	   300-­‐700	  
cells/mm3.	   There	   are	   two	   HIV	   positive	   patients	   for	   whom	   CD4	   counts	   and	  
details	   of	   antiretroviral	   treatment	   details	   could	   not	   be	   traced.	   	   Combination	  
antiretroviral	   therapy	   (cART)	  was	   given	   to	   11	   patients	   prior	   to	   splenectomy.	  
The	   patient	   who	   did	   not	   receive	   cART	   was	   given	   AZT	   monotherapy	   post-­‐
operatively	  -­‐	  she	  was	  pregnant	  at	  the	  time	  of	  splenectomy	  and	  AZT	  was	  initiated	  
at	  28	  weeks	  gestational	  age.	   	  One	  patient	  was	  given	  AZT	  monotherapy	   for	   the	  
treatment	  of	  ITP	  for	  2	  years	  before	  the	  initiation	  of	  cART	  and	  splenectomy.	  	  See	  
Table	  3	  for	  details	  of	  anti-­‐retroviral	  treatment.	  	  Three	  patients	  were	  already	  on	  
cART	   when	   they	   developed	   ITP	   and	   the	   other	   9	   patients	   developed	   ITP	   and	  
were	  subsequently	  put	  onto	  cART.	  	  	  
Table	  3.	  HIV	  positive	  patients:	  CD4	  counts	  and	  ARVs	  
CD4	  (cells/mm3)	  at	  diagnosis	  
(n=10)	  
N	   %	  
<100	   1	   10	  
100-­‐300	   6	   60	  
301-­‐700	   1	   10	  
>700	   2	   20	  
ARVs*	  prior	  to	  splenectomy	   	   	  
AZT,	  3TC,	  EFV	   4	   33	  
D4T,	  3TC,	  EFV	   3	   25	  
TDF,	  3TC,	  EFV	   2	   17	  
AZT,	  3TC,	  NVP	   1	   8	  
D4T,	  3TC,	  NVP	   1	   8	  
NONE**	   1	   8	  
*ARVS	  =	  antiretrovirals:	  AZT	  =	  zidovudine;	  3TC	  =	  lamivudine;	  EFV	  =	  efavirenz;	  NVP	  =	  
nevirapine;	  TDF	  =	  tenofivir;	  	  	  	  	  	  	  	  	  **	  The	  patient	  not	  given	  ARVs	  was	  given	  AZT	  after	  splenectomy	  
 
4. Operative	  information	  
Of	   the	   69	   patients	   for	  whom	  operative	   details	   could	   be	   traced,	   splenectomies	  
were	  by	  open	  laparotomy	  in	  26	  patients	  (38%)	  and	  by	  laparoscopy	  in	  43	  (62%).	  	  
See	   figure	  1	   for	   a	  depiction	  of	  open	  versus	   laparoscopic	   splenectomy	  by	  year.	  	  
The	  median	  platelet	  count	  at	  splenectomy	  was	  187×109/L	  (range:	  6-­‐615×109/L).	  
	   47	  
This	   is	   a	   surprisingly	  high	  number	  and	   reflects	   that	  many	  of	   these	  patients	  
were	   responsive	   to	   steroids,	   but	   were	   steroid	   dependent	   at	   the	   time	   of	  
splenectomy.	  
	  
Median	  time	  to	  splenectomy	  from	  diagnosis	  of	  ITP	  was	  14	  months	  (range	  1-­‐167	  
months);	  in	  the	  HIV	  positive	  population	  it	  was	  8.5months	  (range:	  1-­‐42),	  and	  in	  
the	  HIV	  negative	  population	  30	  months	   (range:	  1-­‐167months);	   this	  was	  a	  non	  
statistically	  significant	  difference	  (z=1.55	  and	  p=0.12	  using	  the	  Wilcoxon	  Rank	  
test).	  	  
	  
The	  median	  discharge	  was	  on	  the	  3rd	  post-­‐operative	  day	  	  (range:	  day	  2-­‐8):	  	  for	  
HIV	  positive	  patients	   it	  was	  day	  2.5	  (range:	  2-­‐6)	  and	  for	  HIV	  negative	  patients	  
day	   3	   (range:	   2-­‐8).	   	   This	   was	   a	   non-­‐statistically	   significant	   difference	   (p=0.5	  
with	  Fisher’s	  exact	  test).	  	  	  
	  
	  The	   intra-­‐operative	   complication	   rate	   for	   splenectomy	   was	   low	   (10%)	   and	  
complications	  included	  conversion	  to	  open	  splenectomy	  for	  bleeding	  (n=2),	  and	  
adhesions	  (n=3).	  	  There	  was	  no	  intra-­‐operative	  mortality.	  
	  
There	  were	  11	  post-­‐operative	  complications	   in	  10	  patients	  (16%	  complication	  
rate).	   The	   most	   common	   post-­‐operative	   complication	   was	   infection.	   Five	  
patients	  developed	   intra-­‐abdominal	   sepsis:	  one	  had	  a	   splenic	  bed	  abscess	  and	  
one	  developed	  a	  subphrenic	  abscess	  (both	  were	  drained	  percutaneously);	  three	  
required	  re-­‐look	  laparotomies	  on	  post-­‐operative	  days	  2,	  4	  and	  11	  respectively.	  .	  
One	  patient	   required	   intensive	  care	  post-­‐operatively	  but	  did	  well	  after	   the	   re-­‐
look	  laparotomy.	  	  Two	  patients	  developed	  wound	  infections	  that	  resolved	  with	  
oral	  antibiotics	  and	  did	  not	  require	  readmission.	  	  	  
	  
Two	  patients	  developed	  post-­‐operative	  thrombosis:	  one	  patient	  presented	  8	  
days	   post-­‐surgery	   with	   a	   pulmonary	   embolism	   (PE)	   and	   the	   other	   patient	  
developed	   mesenteric	   vein.	   The	   patient	   who	   developed	   mesenteric	   vein	  
thrombosis	   also	   had	   wound	   sepsis,	   she	   was	   noted	   at	   splenectomy	   to	   be	  
morbidly	  obese	  (BMI=62).	  	  Neither	  of	  these	  patients	  had	  thrombocytosis	  at	  the	  
time	  of	  presentation	  with	  the	  thrombosis.	  The	  patient	  with	  the	  PE	  had	  a	  platelet	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count	   of	   302×109/L	   and	   the	  patient	  with	  mesenteric	   vein	   thrombosis	   had	   a	  
platelet	  count	  of	  210×109/L.	  
	  
	  	  One	  HIV	  positive	  patient	  developed	  drip-­‐site	   sepsis,	   and	  one	  HIV	  positive	  
patient	  had	  sub	  acute	  small	  bowel	  obstruction	  that	  resolved	  with	  conservative	  
management.	   	   The	   complication	   rate	   in	   the	   HIV	   positive	   patients	   was	   non	  
statistically	   significantly	  different	   to	   the	  HIV	  negative	  patients	   (18%	  and	  16%	  
respectively;	  Fisher’s	  exact	  test	  p=0.59).	  
	  
There	  was	  1	  post-­‐operative	  death	  at	  10	  weeks	  post-­‐surgery	  giving	  a	  90	  day	  
mortality	   rate	   of	   1.38%.	   	   This	   patient	   was	   HIV	   positive,	   had	   had	   an	  
uncomplicated	   splenectomy	  and	  was	  discharged	   on	  day	  2	  post-­‐operation.	   She	  
presented	  again	  ten	  weeks	  later	  in	  septic	  shock	  (with	  an	  unidentified	  organism)	  
and	  required	  inotropes	  and	  dialysis;	  her	  platelet	  count	  remained	  <30×109/L.	  She	  
died	   within	   24hours	   of	   admission.	   	   This	   patient	   had	   received	   the	   23-­‐valent	  
pneumococcal	  vaccine	  as	  an	  inpatient	  one	  day	  prior	  to	  her	  surgery.	  
	  
The	   mean	   discharge	   day	   was	   day	   3	   (range:	   2-­‐8);	   with	   no	   statistically	  
significant	   difference	   in	   the	   HIV	   positive	   (mean:	   2.5;	   range:	   2-­‐6)	   and	   HIV	  
negative	  patient	  groups	  (mean:	  2;	  range:	  2-­‐8);	  with	  a	  p	  value	  of	  0.5	  with	  Fisher’s	  
exact	  test.	  	  See	  table	  4	  for	  operative	  information.	  	  
Table	  4.	  Operative	  information	  
Type	  of	  splenectomy	   N=69	  
Open	  laparotomy	   26	  (38%)	  
Laparoscopic	   43	  (62%)	  
Intra-­operative	  complications	   N=60	  
Mortality	   0	  
Adhesions	  (converted	  to	  open)	   3	  
Bleeding	  (converted	  to	  open)	   2	  
Convert	  to	  open	  reason	  not	  
found	   2	  
Post-­operative	  complications	   N=60	  
Death	  	   1	  
Intra-­‐abdominal	  sepsis	  	   5	  
Wound	  infection	   2	  
Thromboembolic*	   2	  
Drip	  site	  sepsis	   1	  
Sub-­‐acute	  small	  bowel	  
obstruction	   1	  
*one	  pulmonary	  embolism,	  one	  mesenteric	  vein	  thrombosis	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Figure 1.  Number of splenectomies performed by year and type of splenectomy 
 
5. Response	  to	  splenectomy	  	  
Patients	  were	  followed	  up	  for	  a	  mean	  of	  48months	  (range	  2-­‐138months).	  	  Of	  the	  
55	  patients	  for	  whom	  either	  the	  follow-­‐up	  was	  at	  least	  a	  year,	  44	  (80%)	  had	  a	  
complete	   response	   (CI	   69-­‐91%).	   At	   the	   one	   year	   platelet	   count	   there	  was	   no	  
statistically	  significant	  difference	  between	  HIV	  positive	  and	  negative	  patients:	  t	  
test=	   0.39,	   42	   degrees	   of	   freedom,	   p	   value	   0.69.	   	   See	   figure	   2	   for	   a	   box	   plot	  
depicting	  platelet	  count	  at	  one	  year	  for	  HIV	  positive	  and	  negative	  patients.	  	  
	  
At	  one	  month	  89%	  of	  patients	  had	  a	  platelet	   count>100×109/L;	  at	   six	  months	  
82%	  and	  at	   one	  year	  94%	  (this	   is	  different	   to	   the	   rate	  of	   ‘complete	   response’	  
because	   5	   patients	   required	   further	   immunosuppression	   to	   maintain	   this	  
platelet	  count).	  
	  
Eleven	  patients	  did	  not	  have	  a	  complete	  response.	  	  Of	  these	  11	  patients:	  7	  had	  a	  
partial	  response	  and	  4	  had	  no	  response	  to	  splenectomy.	   	   	  All	  11	  patients	  were	  
re-­‐treated	  with	  steroids,	  and	  4	  were	  treated	  with	  azathioprine.	  	  Of	  the	  7	  patients	  
with	   a	   partial	   response,	   6	   of	   the	   7	   patients	   later	   achieved	   platelet	   counts	   of	  	  
>100×109/L.	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and	  4%	  at	  one	  year.	  The	   reason	   for	   this	  decrease	   in	  percentage	   is	  partially	  
attributable	   to	   patient	   mortality	   since	   a	   greater	   proportion	   of	   patients	   with	  
platelets	  <30×109/L	  than	  patients	  with	  platelets	  >30×109/L	  died.	  The	  patients	  
who	  had	  no	  response	  to	  splenectomy	  fared	  poorly	  –	  with	  a	  100%	  mortality	  rate	  
in	   the	   study	   follow-­‐up	   period.	   Compared	   to	   the	   morality	   rate	   of	   4.5%	   in	   the	  
complete	   responders	   this	   is	   a	   statistically	   significant	   different	   (p=0.01).	   See	  
table	  5	   for	  platelet	  count	  post-­‐splenectomy.	   	  Figure	  2	  depicts	  platelet	  count	  at	  
one	  year	  by	  HIV	  status.	  
	  
Table	  5.	  Platelet	  counts	  post	  splenectomy	  
Platelet	  count	  	   1	  month	  (N=59)	   6	  months	  (N=52)	   12	  months	  (N=52)	  
<30	   4	  (7%)	   3	  (6%)	   2	  (4%)	  
30-­‐99	   3	  (5%)	   3	  (6%)	   1	  (2%)	  
≥	  100	   52	  (88%)	   46	  (89%)	   49	  (94%)	  
	  
	  
6. Predictors	  of	  response	  
For	  an	  association	  between	  variables	  and	  complete	  response,	  a	  prevalence	  ratio	  
was	   calculated	   (see	   Table	   6).	   	   The	   variables	   associated	   with	   a	   lower	   rate	   of	  
complete	  response	  have	  a	  value	  less	  than	  one,	  and	  the	  conditions	  with	  a	  higher	  
rate	  of	  complete	  response	  a	  value	  greater	  than	  one.	  	  
	  
The	  variables	  that	  yielded	  prevalence	  ratios	  of	  close	  to	  1	  and	  therefore	  showed	  
neither	   a	   favourable	  nor	  unfavourable	   outcome	  were:	   gender,	  HIV	   status,	   and	  
	   51	  
steroid-­‐resistance.	  
	  
Four	  conditions	  were	  associated	  with	  a	  lower	  response	  rate	  to	  splenectomy,	  but	  
due	  to	  low	  patient	  numbers	  only	  two	  were	  two	  statistically	  significant:	  patients	  
pre-­‐treated	  with	  azathioprine	  and	  those	  with	  diabetes.	  	  	  The	  prevalence	  of	  
complete	  response	  was	  lower	  in	  both	  patients	  who	  were	  Hepatitis	  B	  positive	  
and	  in	  those	  that	  had	  positive	  ANA	  titres,	  although	  neither	  was	  statistically	  
significant.	  	  
	  
There	  was	  no	  significant	  difference	  in	  the	  outcome	  among	  those	  who	  had	  TB	  or	  
SLE.	   	   It	   is	   interesting	   that	   SLE	   patients	   had	   a	   (non	   significant)	   higher	   rate	   of	  
complete	  response	  but	  ANA	  positivity	  was	  associated	  with	  a	  worse	  outcome.	  	  All	  
8	  patients	  with	  SLE	  were	  ANA	  positive;	  but	  10	  were	  ANA	  positive	  and	  did	  not	  
have	   SLE.	   In	   these	   patients	   the	   rate	   of	   complete	   response	  was	   66%	   (CI	   0.28-­‐
1.05)	  and	   if	  ANA	  positive	  and	   the	  patient	  had	  SLE	   the	  complete	  response	  rate	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Table	  6.	  Variables	  and	  rate	  of	  complete	  response	  (N%CR);	  with	  calculated	  
prevalence	  ratios.	  	  
Variables	   N	   N%CR	   Prevalence	  
ratio	  
CI	   P	  value	  
	   	   	   	   	   	  
Gender	   	   	   	   	   	  
Male	   11	   9	  (82)	   0.97	  	   0.71-­‐1.33	   1.0	  
Female	   44	   35	  (80)	   	   	   	  
HIV	  status	   	   	   	   	   	  
Positive	   9	   7	  (78)	   0.99	   0.67-­‐1.45	   1.0	  
Negative	   38	   30	  (79)	  	   	   	   	  
Hepatitis	  B	  	   	   	   	   	   	  
Positive	   3	   2(66)	   0.83	   0.37-­‐1.9	   0.53	  
Negative	   25	   20(80)	   	   	   	  
ANA	   	   	   	   	   	  
Positive	   18	   14	  (78)	   0.84	   0.63-­‐1.12	   0.36	  
Negative	   14	   13(93)	   	   	   	  
Diabetes	   	   	   	   	   	  
Yes	   5	   2	  (40)	   0.47	   0.83-­‐1.51	   0.04	  
No	   48	   41	  (85)	   	   	   	  
TB	   	   	   	   	   	  
Positive	   6	   5(83)	   1.25	   0.16-­‐9.64	   1.0	  
Negative	   49	   39(80)	   	   	   	  
Azathioprine	   	  	   	   	   	   	  
Yes	   21	   13(62)	   0.62	   0.45-­‐0.87	   0.001	  
No	   27	   27(100)	   	   	   	  
Steroid	  resistant	   	  	   	   	   	   	  
Yes	   22	   17(77)	   0.92	   0.7-­‐1.21	   0.72	  
No	   31	   26(84)	   	   	   	  
SLE	   	   	   	   	   	  
Yes	   8	   7	  (88)	   1.12	   0.83-­‐1.51	   1.0	  
No	   48	   36(78)	   	   	   	  
 
N=	  number	  with	  variable	  and	  for	  whom	  complete	  response	  rate	  known.	  P	  value	  calculated	  
with	  Fisher’s	  exact	  test. 
 
7. Mortality	  and	  Morbidity	  
Seven	  patients	  died	   in	   the	   follow	  up	  period.	  Six	  patients	  with	  recorded	  deaths	  
were	   HIV	   negative;	   4	   were	   female	   and	   2	   male	   and	   one	   was	   an	   HIV	   positive	  
female.	   	  Four	  of	  the	  seven	  deaths	  occurred	  in	  patients	  who	  had	  no	  response	  to	  
splenectomy.	  
	  
Four	  deaths	  may	  have	  been	  related	  to	  the	  splenectomy:	  one	  was	  a	  young	  male	  
(age	   24)	  who	  died	   from	  overwhelming	  pneumococcal	   sepsis	   proven	   on	   blood	  
and	   CSF	   culture	   -­‐	   he	   had	   received	   the	   pneumococcal	   vaccine;	   but	   died	   at	  
18months	   post	   splenectomy.	   	   The	   second	  was	   a	   female	   age	   50	  with	   diabetes	  
who	  died	   from	  a	  cerebrovascular	  event	  6	  months	  post	  splenectomy,	  of	  note	   is	  
	   53	  
that	  her	  platelet	  count	  at	   the	  time	  of	  CVA	  was	  1214×109/L	  which	  may	  have	  
caused	   the	   CVA.	   	   The	   third	   was	   an	   HIV	   positive	   female	   who	   died	   from	   an	  
unidentified	  source	  of	  sepsis	  at	  10	  weeks	  post	  op;	  she	  presented	  in	  septic	  shock	  
and	  renal	  failure	  requiring	  dialysis.	  The	  fourth	  death	  was	  in	  a	  patient	  who	  had	  a	  
partial	  response	  to	  splenectomy	  who	  died	  from	  a	  ruptured	  appendix	  and	  sepsis	  
at	  68	  months	  post-­‐splenectomy.	  
	  
The	  other	  three	  deaths	  were	  likely	  unrelated	  to	  splenectomy,	  but	  all	  three	  of	  the	  
deaths	  were	  in	  patients	  with	  no	  response	  to	  splenectomy:	  One	  patient	  died	  from	  
an	   intra-­‐cerebral	  haemorrhage	  at	  91	  months	  post-­‐splenectomy	  with	  a	  platelet	  
count<10×109/L;	   one	   died	   from	   an	   unknown	   cause	   at	   52	   months	   post	  
splenectomy	  with	  a	  platelet	  count	  of	  26×109/L;	  one	  died	  from	  adenocarcinoma	  
of	  the	  prostate	  at	  6	  months	  post-­‐splenectomy	  with	  a	  platelet	  count	  of	  17×109/L.	  	  
	  
See	   Table	   7	   for	   all-­‐cause	   mortality	   by	   gender	   and	   HIV	   status	   as	   well	   as	   the	  
corresponding	   Kaplan-­‐Meier	   survival	   estimates,	   only	   patients	   for	   whom	   HIV	  
status	  was	  known	  were	  included	  in	  the	  analysis	  (Figure	  3	  and	  4).	  Male	  gender	  
was	  associated	  with	  a	  non-­‐statistically	  significant	  higher	  mortality	  rate	  (despite	  
fewer	  deaths,	  because	  of	   the	   relatively	   fewer	  months	  of	   follow-­‐up).	   	   	  HIV	  was	  
not	  associated	  with	  a	  statistically	  significant	  difference	  in	  mortality.	  
	  
	  









Figure	  4:	  Kaplan-­‐Meier	  survival	  estimates	  by	  HIV	  status	  
Figure	  4:	  Kaplan-­‐Meier	  survival	  estimates	  by	  gender	  




Table	   7.	   	   All-­‐cause	   mortality	   by	   patient-­‐time	   (months),	   (p	   value	   calculated	   by	  
Fisher’s	  exact	  test 
	  
Variable	   Person	  
time	  
(months)	  





95%	  CI	   P=	  
HIV	  status	   	   	   	   	   	   	  
Positive	   854	   1	   1.17	   0.16-­‐8.31	   1.00	  
Negative	   5246	   6	   1.14	   0.51-­‐2.54	   	  
Gender	   	   	   	   	   	  
Male	  	   1087	   2	   1.83	   0.46-­‐7.35	   0.66	  
Female	   5933	   5	   0.84	   0.35-­‐2.02	   	  
Conclusions	  and	  Recommendations	  
Splenectomy	  remains	  an	  effective	  method	  of	  managing	  ITP	  in	  both	  HIV	  positive	  
and	  negative	  patients.	  	  The	  complete	  treatment	  response	  in	  this	  study	  of	  80%	  is	  
within	  the	  range	  previously	  reported	  in	  the	  literature	  of	  60-­‐80%	  (3,5,6).	  	  	  One	  of	  
the	  strengths	  of	  this	  study	  is	  the	  long	  follow-­‐up	  time;	  a	  mean	  follow-­‐up	  of	  
48months	  is	  significantly	  longer	  than	  most	  studies	  of	  splenectomy	  for	  ITP	  (3,5,6).	  
The	  complete	  response	  rate	  to	  splenectomy	  appears	  higher	  than	  that	  reported	  
for	  rituximab	  (8)	  or	  the	  new	  thrombopoetin	  agonists	  (10).	  
	  
The	  patients	  included	  in	  this	  study	  were	  a	  heavily	  pre-­‐treated	  group	  (100%	  
given	  oral	  corticosteroids	  at	  a	  dose	  of	  1-­‐2mg/kg/d	  and	  33%	  given	  
azathioprine),	  which	  is	  typical	  of	  a	  study	  showing	  outcomes	  of	  second-­‐line	  
therapy.	  	  It	  is	  interesting	  to	  note	  that	  in	  the	  patients	  who	  had	  no	  response	  there	  
was	  a	  100%	  (n=4)	  mortality;	  however	  in	  the	  patients	  with	  a	  partial	  response	  to	  
splenectomy,	  six	  of	  the	  seven	  patients	  later	  had	  a	  good	  response	  with	  platelet	  
counts	  of	  	  >100×109/L,	  maintained	  for	  the	  duration	  of	  follow-­‐up.	  	  This	  is	  also	  in	  
keeping	  with	  the	  literature	  which	  has	  shown	  that	  patients	  with	  refractory	  ITP	  
after	  splenectomy	  have	  a	  good	  response	  to	  additional	  treatment	  (3).	  	  	  	  
The	  poorer	  response	  (although	  not	  statistically	  significant	  in	  this	  study)	  of	  
patients	  with	  ANA	  positivity	  has	  been	  previously	  described	  in	  a	  large	  cohort	  
study	  by	  Li	  et	  al(11).	  	  This	  requires	  further	  investigation,	  but	  this	  may	  be	  a	  sub-­‐
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group	  of	  patients	  in	  whom	  further	  medical	  management	  is	  indicated	  prior	  to	  
splenectomy.	  	  
	  
Although	  our	  HIV	  positive	  cohort	  was	  small	  (n=12),	  the	  treatment	  response	  
in	  this	  group	  was	  not	  significantly	  different	  to	  the	  HIV	  negative	  cohort.	  	  This	  is	  
also	  in	  keeping	  with	  the	  literature	  where	  the	  response	  rate	  to	  splenectomy	  in	  
the	  HIV	  positive	  population	  was	  92%	  and	  a	  long-­‐term	  (6	  month	  response)	  was	  
seen	  in	  82%	  of	  cases	  (5).	  	  The	  CD4	  count	  at	  diagnosis	  of	  ITP	  well	  demonstrated	  
the	  typical	  bimodal	  distribution	  of	  ITP	  in	  HIV	  -­‐	  showing	  ITP	  early	  in	  HIV	  with	  
CD4	  counts	  higher	  than	  700/mm3,	  and	  late	  in	  HIV	  with	  CD4	  counts	  less	  than	  
300/mm3.	  	  A	  limitation	  in	  our	  study	  was	  the	  small	  number	  of	  HIV	  positive	  
patients,	  which	  led	  to	  results	  not	  being	  statistically	  significant.	  
	  
The	  complications,	  morbidity	  and	  mortality	  associated	  with	  splenectomy	  
were	  not	  statistically	  significantly	  higher	  in	  the	  HIV	  positive	  population	  than	  in	  
the	  negative	  population	  (18%	  and	  16%	  respectively;	  Fisher’s	  exact	  test	  p=0.59).	  	  
Our	  complication	  rates	  were	  slightly	  higher	  than	  reported(3),	  but	  this	  is	  difficult	  
to	  interpret	  since	  the	  investigators	  did	  not	  make	  it	  clear	  what	  they	  considered	  
to	  be	  ‘complications’	  and	  we	  also	  included	  minor	  complications	  such	  as	  drip	  site	  
sepsis.	  	  	  Our	  patient	  population	  is	  mostly	  of	  a	  low	  socio-­‐economic	  status,	  as	  we	  
treat	  patients	  who	  generally	  have	  no	  medical	  insurance,	  and	  this	  might	  have	  
influenced	  the	  post-­‐operative	  complication	  rate	  (due	  to	  poor	  sanitation,	  being	  
without	  access	  to	  running	  water,	  poor	  nutrition,	  overcrowding,	  and	  more	  
difficulty	  in	  accessing	  healthcare	  as	  possible	  factors).	  	  
	  
Within	  the	  current	  treatment	  milieu	  with	  a	  range	  of	  options	  now	  available	  to	  
offer	  to	  patients	  who	  fail	  steroid	  therapy,	  one	  needs	  to	  compare	  the	  outcomes	  
and	  complication	  rates	  of	  splenectomy	  with	  those	  of	  the	  newer	  agents.	  	  Patients	  
need	  to	  be	  informed	  that	  although	  the	  reluctance	  to	  undergo	  surgery	  is	  
understandable,	  splenectomy	  is	  an	  operation	  with	  low	  morbidity	  and	  extremely	  
low	  mortality	  which	  may	  be	  safer	  than	  the	  new	  medical	  treatments	  available	  as	  
well	  as	  more	  effective.	  	  
	  
If	  we	  compare	  the	  outcome	  of	  splenectomy	  with	  the	  best	  data	  for	  rituximab	  (a	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meta-­‐analysis),	  rituximab	  showed	  a	  complete	  response	  rate	  of	  41%	  (95%	  CI:	  
0·33–0·51)	  for	  346	  patients	  (7);	  and	  the	  author’s	  conclusion	  was	  that	  rituximab	  
should	  be	  used	  earlier	  in	  non-­‐splenctomised	  patients;	  in	  this	  large	  review	  
however	  they	  did	  not	  look	  at	  side-­‐effects	  and	  rate	  of	  complications	  or	  cost	  
associated	  with	  rituximab	  therapy	  before	  making	  the	  recommendation	  that	  it	  
should	  be	  offered	  before	  splenectomy.	  	  In	  a	  separate	  article,	  of	  35	  patients	  	  there	  
were	  two	  deaths	  following	  rituximab;	  one	  of	  which,	  a	  pneumonia	  at	  13	  weeks,	  
was	  possibly	  related	  to	  rituximab	  mediated	  immunosupression(9).	  	  It	  is	  
therefore	  not	  an	  innocuous	  treatment	  and	  patients	  need	  to	  be	  informed	  of	  the	  
risks	  prior	  to	  treatment.	  	  In	  our	  setting	  response	  rates,	  complication	  rates,	  as	  
well	  as	  costs	  are	  considered	  and	  with	  the	  current	  body	  of	  evidence	  it	  is	  
reasonable	  to	  consider	  rituximab	  only	  after	  splenectomy.	  	  
	  
Considering	  the	  TPO	  agonists	  romiplostim	  and	  eltrombopag,	  these	  drugs	  
have	  demonstrated	  durable	  response	  rates	  (platelet	  count	  more	  than	  100	  
×109/L	  at	  6	  to	  8weeks)	  in	  50	  to	  60%	  of	  patients	  as	  long	  as	  treatment	  is	  
maintained(12;13).	  Complications	  on	  treatment	  with	  eltrombopag	  include	  an	  
increase	  in	  alanine	  aminotransferase	  and	  indirect	  bilirubin	  and	  an	  increase	  in	  
thrombotic	  events.	  	  More	  studies	  are	  needed	  to	  investigate	  the	  role	  of	  this	  
treatment;	  presently	  it	  remains	  that	  these	  agents	  could	  be	  used	  in	  the	  setting	  of	  
failure	  of	  splenectomy	  and	  other	  second-­‐line	  agents.	  
	  
Before	  considering	  splenectomy	  in	  any	  patient	  one	  has	  to	  weigh	  up	  the	  risk	  
of	  bleeding	  and	  compare	  that	  to	  the	  risks	  of	  splenectomy;	  the	  risk	  of	  bleeding	  in	  
ITP	  is	  only	  higher	  than	  the	  general	  population	  at	  a	  platelet	  count	  of	  
<30×109/L(14)	  and	  the	  risk	  of	  fatal	  bleeding	  is	  0.02	  to	  0.04	  cases	  per	  patient-­‐
year(15).	  	  The	  platelet	  count	  at	  which	  the	  risks	  of	  splenectomy	  are	  less	  than	  the	  
risk	  of	  bleeding	  is	  likely	  to	  be	  even	  lower	  than	  30×109/L.	  	  In	  our	  study	  the	  
median	  platelet	  count	  prior	  to	  splenectomy	  was	  high,	  but	  these	  values	  were	  
only	  maintained	  prior	  to	  surgery	  by	  continuous	  high	  doses	  of	  prednisone	  as	  
well	  as	  other	  immunosuppressives.	  
	  
The	  results	  from	  this	  study	  are	  promising	  and	  suggest	  that	  splenectomy	  
should	  remain	  second-­‐line	  treatment	  for	  ITP	  as	  it	  is	  relatively	  safe	  as	  well	  as	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effective	  for	  the	  treatment	  of	  ITP,	  including	  ITP	  secondary	  to	  HIV.	  	  	  The	  
complication	  and	  success	  rates	  following	  splenectomy	  in	  this	  study	  is	  similar	  to	  
the	  international	  literature,	  indicating	  that	  our	  level	  of	  operative	  expertise	  and	  
pre	  and	  post-­‐operative	  care	  is	  of	  an	  international	  standard.	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